blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2493466

EP2493466 - NOVEL ANTITUMORAL USE OF CABAZITAXEL [Right-click to bookmark this link]
StatusOpposition rejected
Status updated on  19.09.2025
Database last updated on 18.03.2026
FormerThe patent has been granted
Status updated on  05.02.2021
FormerGrant of patent is intended
Status updated on  31.01.2021
FormerExamination is in progress
Status updated on  28.04.2017
Most recent event   Tooltip25.11.2025New entry: Number of petition for review 
25.11.2025New entry: Petitioner in petition for review 
Applicant(s)For all designated states
SANOFI
46 avenue de la Grande Armée
75017 Paris / FR
[2025/07]
Former [2021/10]For all designated states
Sanofi Mature IP
54 rue la Boétie
75008 Paris / FR
Former [2020/02]For all designated states
Sanofi Mature IP
54 rue la Boétie
75008 Paris / FR
Former [2012/36]For all designated states
Aventis Pharma S.A.
20, avenue Raymond Aron
92160 Antony / FR
Inventor(s)01 / GUPTA, Sunil
c/o Sanofi-Aventis US. Inc.
1041 Routes 202-206 Mail Code: D-303A
Bridgewater, New Jersey 08807 / US
 [2012/36]
Representative(s)J A Kemp LLP
80 Turnmill Street
London EC1M 5QU / GB
[N/P]
Former [2021/10]J A Kemp LLP
14 South Square
Gray's Inn
London WC1R 5JJ / GB
Former [2012/36]Gaslonde, Aude, et al
Sanofi-Aventis Département Brevets 174, Avenue de France
75013 Paris / FR
Application number, filing date10782039.127.10.2010
[2021/10]
WO2010IB54866
Priority number, dateUS20090256160P29.10.2009         Original published format: US 256160 P
US20100293903P11.01.2010         Original published format: US 293903 P
US20100355834P17.06.2010         Original published format: US 355834 P
US20100355888P17.06.2010         Original published format: US 355888 P
US20100369929P02.08.2010         Original published format: US 369929 P
US20100383933P17.09.2010         Original published format: US 383933 P
US20100389969P05.10.2010         Original published format: US 389969 P
[2012/36]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2011051894
Date:05.05.2011
Language:EN
[2011/18]
Type: A1 Application with search report 
No.:EP2493466
Date:05.09.2012
Language:EN
The application published by WIPO in one of the EPO official languages on 05.05.2011 takes the place of the publication of the European patent application.
[2012/36]
Type: B1 Patent specification 
No.:EP2493466
Date:10.03.2021
Language:EN
[2021/10]
Search report(s)International search report - published on:EP05.05.2011
ClassificationIPC:A61K31/164, A61K31/56, A61K45/06, A61P35/00
[2012/36]
CPC:
A61K31/337 (EP,KR,US); A61K31/164 (EP,KR,US); A61K31/56 (EP,KR,US);
A61K31/573 (EP,KR,US); A61K38/193 (EP,KR,US); A61K45/06 (EP,KR,US);
A61P13/08 (EP); A61P15/00 (EP); A61P25/16 (EP);
A61P35/00 (EP); A61P35/04 (EP); A61P43/00 (EP) (-)
C-Set:
A61K31/164, A61K2300/00 (EP,US);
A61K31/337, A61K2300/00 (US,EP);
A61K31/56, A61K2300/00 (US,EP);
A61K31/573, A61K2300/00 (US,EP)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2020/38]
Former [2012/36]AL,  AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MK,  MT,  NL,  NO,  PL,  PT,  RO,  RS,  SE,  SI,  SK,  SM,  TR 
Extension statesBA29.05.2012
ME29.05.2012
TitleGerman:NEUE ANTITUMORALE VERWENDUNG VON CABAZITAXEL[2012/36]
English:NOVEL ANTITUMORAL USE OF CABAZITAXEL[2012/36]
French:NOUVELLE UTILISATION ANTITUMORALE DU CABAZITAXEL[2012/36]
Entry into regional phase29.05.2012National basic fee paid 
29.05.2012Designation fee(s) paid 
29.05.2012Examination fee paid 
Examination procedure29.08.2011Request for preliminary examination filed
International Preliminary Examining Authority: EP
29.05.2012Examination requested  [2012/36]
28.12.2012Amendment by applicant (claims and/or description)
26.05.2014Despatch of a communication from the examining division (Time limit: M06)
28.11.2014Reply to a communication from the examining division
31.01.2017Observations by third parties
20.04.2017Despatch of a communication from the examining division (Time limit: M06)
26.10.2017Reply to a communication from the examining division
21.11.2017Observations by third parties
06.02.2018Despatch of a communication from the examining division (Time limit: M06)
14.08.2018Reply to a communication from the examining division
08.11.2018Despatch of a communication from the examining division (Time limit: M06)
17.05.2019Reply to a communication from the examining division
19.07.2019Observations by third parties
28.10.2019Despatch of a communication from the examining division (Time limit: M06)
07.05.2020Reply to a communication from the examining division
13.05.2020Observations by third parties
03.06.2020Observations by third parties
08.06.2020Observations by third parties
10.07.2020Despatch of a communication from the examining division (Time limit: M04)
24.07.2020Observations by third parties
17.09.2020Reply to a communication from the examining division
25.09.2020Observations by third parties
02.10.2020Observations by third parties
19.01.2021Cancellation of oral proceeding that was planned for 04.02.2021
27.01.2021Observations by third parties
01.02.2021Communication of intention to grant the patent
01.02.2021Fee for grant paid
01.02.2021Fee for publishing/printing paid
01.02.2021Receipt of the translation of the claim(s)
04.02.2021Date of oral proceedings (cancelled)
Divisional application(s)EP21155421.7   Application refused  : 28.06.2021
The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  26.05.2014
Opposition(s)Opponent(s)01  10.03.2021  12.03.2021  ADMISSIBLE
Glenmark Pharmaceuticals Europe Ltd
Building 2
Croxley Park
Watford
WD18 8YA / GB
Opponent's representative
Brand Murray Fuller LLP
50 Eastcastle Street
London W1W 8EA / GB
 02  10.03.2021  07.12.2021  ADMISSIBLE
Accord Healthcare Ltd
Sage House
319 Pinner Road
North Harrow Middlesex
HA1 4HF / GB
Opponent's representative
Bardehle Pagenberg S.L.
Avenida Diagonal 598, 3º, 1ª
08021 Barcelona / ES
 03  10.03.2021  19.11.2021  WITHDRAWN
Teva Pharmaceutical Industries Ltd.
124 Dvora HaNevi'a St.
6944020 Tel Aviv / IL
Opponent's representative
Kraus & Lederer PartGmbB
Thomas-Wimmer-Ring 15
80539 München / DE
 04  12.03.2021  07.06.2022  WITHDRAWN
EVER Valinject GmbH
Oberburgau 3
4866 Unterach am Attersee / AT
Opponent's representative
SONN Patentanwälte GmbH & Co KG
Riemergasse 14
1010 Wien / AT
 05  12.03.2021  09.12.2021  ADMISSIBLE
Zentiva k.s.
U kabelovny 130
10237 Praha 10 / CZ
Opponent's representative
Greiner, Elisabeth
df-mp Patentanwälte Rechtsanwälte PartG mbB
Theatinerstraße 16
80333 München / DE
 06  22.03.2021  12.03.2025  WITHDRAWN
medac Gesellschaft für klinische Spezialpräparate mbH
Theaterstrasse 6
22880 WEDEL / DE
Opponent's representative
Uexküll & Stolberg
Partnerschaft von
Patent- und Rechtsanwälten mbB
Beselerstraße 4
22607 Hamburg / DE
 07  23.03.2021  10.12.2021  ADMISSIBLE
Fresenius Kabi Deutschland GmbH
Else-Kröner-Str. 1
61352 Bad Homburg / DE
Opponent's representative
Fresenius Kabi Deutschland GmbH
Patent Department
Else-Kröner-Straße 1
61352 Bad Homburg / DE
 08  31.03.2021  10.09.2021  ADMISSIBLE
Dr. Reddy's Laboratories Ltd./ Betapharm Arzneimittel GmbH
8-2-337 Road No. 3 /Kobelweg 95
Banjara Hills
Hyderabad
500034 Telangana IN / 86156 Augsburg DE / IN
Opponent's representative
Maiwald GmbH
Elisenhof
Elisenstraße 3
80335 München / DE
 09  08.06.2021  10.06.2021  ADMISSIBLE
Generics (U.K.) Limited
Building 4, Trident Place
Mosquito Way
Hatfield Herts AL10 9UL / GB
Opponent's representative
Elkington and Fife LLP
Prospect House
8 Pembroke Road
Sevenoaks, Kent TN13 1XR / GB
 10  03.12.2021  07.12.2021  ADMISSIBLE
Vossius & Partner Patentanwälte Rechtsanwälte mbB
Siebertstrasse 3
81675 München / DE
Opponent's representative
Vossius & Partner Patentanwälte Rechtsanwälte mbB
Siebertstraße 3
81675 München / DE
 11  09.12.2021  13.12.2021  ADMISSIBLE
STADA Arzneimittel AG
Stadastrasse 2-18
61118 Bad Vilbel / DE
Opponent's representative
Hamm&Wittkopp Patentanwälte PartmbB
Jungfernstieg 38
20354 Hamburg / DE
 12  10.12.2021  14.12.2021  ADMISSIBLE
Maiwald GmbH
Postfach 33 05 23
80065 München / DE
Opponent's representative
Maiwald GmbH
Elisenhof
Elisenstraße 3
80335 München / DE
 13  30.08.2024  30.09.2024  INTERVENTION ADMISSIBLE
Accord Healthcare S.L.U.
World Trade Center
Moll de Barcelona s/n
Edifici Est, 6th floor
08039 Barcelona / ES
Opponent's representative
Bardehle Pagenberg S.L.
Avenida Diagonal 598, 3º, 1ª
08021 Barcelona / ES
 [2025/24]
Former [2025/16]
Opponent(s)01  10.03.2021  12.03.2021  ADMISSIBLE
Glenmark Pharmaceuticals Europe Ltd
Building 2
Croxley Park
Watford
WD18 8YA / GB
Opponent's representative
Brand Murray Fuller LLP
50 Eastcastle Street
London W1W 8EA / GB
 02  10.03.2021  07.12.2021  ADMISSIBLE
Accord Healthcare Ltd
Sage House
319 Pinner Road
North Harrow Middlesex
HA1 4HF / GB
Opponent's representative
Aera A/S
Niels Hemmingsens Gade 10, 5th Floor
1153 Copenhagen K / DK
 03  10.03.2021  19.11.2021  WITHDRAWN
Teva Pharmaceutical Industries Ltd.
124 Dvora HaNevi'a St.
6944020 Tel Aviv / IL
Opponent's representative
Kraus & Lederer PartGmbB
Thomas-Wimmer-Ring 15
80539 München / DE
 04  12.03.2021  07.06.2022  WITHDRAWN
EVER Valinject GmbH
Oberburgau 3
4866 Unterach am Attersee / AT
Opponent's representative
SONN Patentanwälte GmbH & Co KG
Riemergasse 14
1010 Wien / AT
 05  12.03.2021  09.12.2021  ADMISSIBLE
Zentiva k.s.
U kabelovny 130
10237 Praha 10 / CZ
Opponent's representative
Greiner, Elisabeth
df-mp Patentanwälte Rechtsanwälte PartG mbB
Theatinerstraße 16
80333 München / DE
 06  22.03.2021  12.03.2025  WITHDRAWN
medac Gesellschaft für klinische Spezialpräparate mbH
Theaterstrasse 6
22880 WEDEL / DE
Opponent's representative
Uexküll & Stolberg
Partnerschaft von
Patent- und Rechtsanwälten mbB
Beselerstraße 4
22607 Hamburg / DE
 07  23.03.2021  10.12.2021  ADMISSIBLE
Fresenius Kabi Deutschland GmbH
Else-Kröner-Str. 1
61352 Bad Homburg / DE
Opponent's representative
Fresenius Kabi Deutschland GmbH
Patent Department
Else-Kröner-Straße 1
61352 Bad Homburg / DE
 08  31.03.2021  10.09.2021  ADMISSIBLE
Dr. Reddy's Laboratories Ltd./ Betapharm Arzneimittel GmbH
8-2-337 Road No. 3 /Kobelweg 95
Banjara Hills
Hyderabad
500034 Telangana IN / 86156 Augsburg DE / IN
Opponent's representative
Maiwald GmbH
Elisenhof
Elisenstraße 3
80335 München / DE
 09  08.06.2021  10.06.2021  ADMISSIBLE
Generics (U.K.) Limited
Building 4, Trident Place
Mosquito Way
Hatfield Herts AL10 9UL / GB
Opponent's representative
Elkington and Fife LLP
Prospect House
8 Pembroke Road
Sevenoaks, Kent TN13 1XR / GB
 10  03.12.2021  07.12.2021  ADMISSIBLE
Vossius & Partner Patentanwälte Rechtsanwälte mbB
Siebertstrasse 3
81675 München / DE
Opponent's representative
Vossius & Partner Patentanwälte Rechtsanwälte mbB
Siebertstraße 3
81675 München / DE
 11  09.12.2021  13.12.2021  ADMISSIBLE
STADA Arzneimittel AG
Stadastrasse 2-18
61118 Bad Vilbel / DE
Opponent's representative
Hamm&Wittkopp Patentanwälte PartmbB
Jungfernstieg 38
20354 Hamburg / DE
 12  10.12.2021  14.12.2021  ADMISSIBLE
Maiwald GmbH
Postfach 33 05 23
80065 München / DE
Opponent's representative
Maiwald GmbH
Elisenhof
Elisenstraße 3
80335 München / DE
 13  30.08.2024  30.09.2024  INTERVENTION ADMISSIBLE
Accord Healthcare S.L.U.
World Trade Center
Moll de Barcelona s/n
Edifici Est, 6th floor
08039 Barcelona / ES
Opponent's representative
Aera A/S
Niels Hemmingsens Gade 10, 5th Floor
1153 Copenhagen K / DK
Former [2024/41]
Opponent(s)01  10.03.2021  12.03.2021  ADMISSIBLE
Glenmark Pharmaceuticals Europe Ltd
Building 2
Croxley Park
Watford
WD18 8YA / GB
Opponent's representative
Brand Murray Fuller LLP
50 Eastcastle Street
London W1W 8EA / GB
 02  10.03.2021  07.12.2021  ADMISSIBLE
Accord Healthcare Ltd
Sage House
319 Pinner Road
North Harrow Middlesex
HA1 4HF / GB
Opponent's representative
Aera A/S
Niels Hemmingsens Gade 10, 5th Floor
1153 Copenhagen K / DK
 03  10.03.2021  19.11.2021  WITHDRAWN
Teva Pharmaceutical Industries Ltd.
124 Dvora HaNevi'a St.
6944020 Tel Aviv / IL
Opponent's representative
Kraus & Lederer PartGmbB
Thomas-Wimmer-Ring 15
80539 München / DE
 04  12.03.2021  07.06.2022  WITHDRAWN
EVER Valinject GmbH
Oberburgau 3
4866 Unterach am Attersee / AT
Opponent's representative
SONN Patentanwälte GmbH & Co KG
Riemergasse 14
1010 Wien / AT
 05  12.03.2021  09.12.2021  ADMISSIBLE
Zentiva k.s.
U kabelovny 130
10237 Praha 10 / CZ
Opponent's representative
Greiner, Elisabeth
df-mp Dörries Frank-Molnia & Pohlman
Patentanwälte Rechtsanwälte PartG mbB
Theatinerstraße 16
80333 München / DE
 06  22.03.2021  13.12.2021  ADMISSIBLE
medac Gesellschaft für klinische Spezialpräparate mbH
Theaterstrasse 6
22880 WEDEL / DE
Opponent's representative
Uexküll & Stolberg
Partnerschaft von
Patent- und Rechtsanwälten mbB
Beselerstraße 4
22607 Hamburg / DE
 07  23.03.2021  10.12.2021  ADMISSIBLE
Fresenius Kabi Deutschland GmbH
Else-Kröner-Str. 1
61352 Bad Homburg / DE
Opponent's representative
Fresenius Kabi Deutschland GmbH
Patent Department
Else-Kröner-Straße 1
61352 Bad Homburg / DE
 08  31.03.2021  10.09.2021  ADMISSIBLE
Dr. Reddy's Laboratories Ltd./ Betapharm Arzneimittel GmbH
8-2-337 Road No. 3 /Kobelweg 95
Banjara Hills
Hyderabad
500034 Telangana IN / 86156 Augsburg DE / IN
Opponent's representative
Maiwald GmbH
Elisenhof
Elisenstraße 3
80335 München / DE
 09  08.06.2021  10.06.2021  ADMISSIBLE
Generics (U.K.) Limited
Building 4, Trident Place
Mosquito Way
Hatfield Herts AL10 9UL / GB
Opponent's representative
Elkington and Fife LLP
Prospect House
8 Pembroke Road
Sevenoaks, Kent TN13 1XR / GB
 10  03.12.2021  07.12.2021  ADMISSIBLE
Vossius & Partner Patentanwälte Rechtsanwälte mbB
Siebertstrasse 3
81675 München / DE
Opponent's representative
Vossius & Partner Patentanwälte Rechtsanwälte mbB
Siebertstraße 3
81675 München / DE
 11  09.12.2021  13.12.2021  ADMISSIBLE
STADA Arzneimittel AG
Stadastrasse 2-18
61118 Bad Vilbel / DE
Opponent's representative
Hamm&Wittkopp Patentanwälte PartmbB
Jungfernstieg 38
20354 Hamburg / DE
 12  10.12.2021  14.12.2021  ADMISSIBLE
Maiwald GmbH
Postfach 33 05 23
80065 München / DE
Opponent's representative
Maiwald GmbH
Elisenhof
Elisenstraße 3
80335 München / DE
 13  30.08.2024  04.09.2024  INTERVENTION
Accord Healthcare S.L.U.
World Trade Center
Moll de Barcelona s/n
Edifici Est, 6th floor
08039 Barcelona / ES
Opponent's representative
Aera A/S
Niels Hemmingsens Gade 10, 5th Floor
1153 Copenhagen K / DK
Former [2024/15]
Opponent(s)01  10.03.2021  12.03.2021  ADMISSIBLE
Glenmark Pharmaceuticals Europe Ltd
Building 2
Croxley Park
Watford
WD18 8YA / GB
Opponent's representative
Brand Murray Fuller LLP
50 Eastcastle Street
London W1W 8EA / GB
 02  10.03.2021  07.12.2021  ADMISSIBLE
Accord Healthcare Ltd
Sage House
319 Pinner Road
North Harrow Middlesex
HA1 4HF / GB
Opponent's representative
Aera A/S
Niels Hemmingsens Gade 10, 5th Floor
1153 Copenhagen K / DK
 03  10.03.2021  19.11.2021  WITHDRAWN
Teva Pharmaceutical Industries Ltd.
124 Dvora HaNevi'a St.
6944020 Tel Aviv / IL
Opponent's representative
Kraus & Lederer PartGmbB
Thomas-Wimmer-Ring 15
80539 München / DE
 04  12.03.2021  07.06.2022  WITHDRAWN
EVER Valinject GmbH
Oberburgau 3
4866 Unterach am Attersee / AT
Opponent's representative
SONN Patentanwälte GmbH & Co KG
Riemergasse 14
1010 Wien / AT
 05  12.03.2021  09.12.2021  ADMISSIBLE
Zentiva k.s.
U kabelovny 130
10237 Praha 10 / CZ
Opponent's representative
Greiner, Elisabeth
df-mp Dörries Frank-Molnia & Pohlman
Patentanwälte Rechtsanwälte PartG mbB
Theatinerstraße 16
80333 München / DE
 06  22.03.2021  13.12.2021  ADMISSIBLE
medac Gesellschaft für klinische Spezialpräparate mbH
Theaterstrasse 6
22880 WEDEL / DE
Opponent's representative
Uexküll & Stolberg
Partnerschaft von
Patent- und Rechtsanwälten mbB
Beselerstraße 4
22607 Hamburg / DE
 07  23.03.2021  10.12.2021  ADMISSIBLE
Fresenius Kabi Deutschland GmbH
Else-Kröner-Str. 1
61352 Bad Homburg / DE
Opponent's representative
Fresenius Kabi Deutschland GmbH
Patent Department
Else-Kröner-Straße 1
61352 Bad Homburg / DE
 08  31.03.2021  10.09.2021  ADMISSIBLE
Dr. Reddy's Laboratories Ltd./ Betapharm Arzneimittel GmbH
8-2-337 Road No. 3 /Kobelweg 95
Banjara Hills
Hyderabad
500034 Telangana IN / 86156 Augsburg DE / IN
Opponent's representative
Maiwald GmbH
Elisenhof
Elisenstraße 3
80335 München / DE
 09  08.06.2021  10.06.2021  ADMISSIBLE
Generics (U.K.) Limited
Building 4, Trident Place
Mosquito Way
Hatfield Herts AL10 9UL / GB
Opponent's representative
Elkington and Fife LLP
Prospect House
8 Pembroke Road
Sevenoaks, Kent TN13 1XR / GB
 10  03.12.2021  07.12.2021  ADMISSIBLE
Vossius & Partner Patentanwälte Rechtsanwälte mbB
Siebertstrasse 3
81675 München / DE
Opponent's representative
Vossius & Partner Patentanwälte Rechtsanwälte mbB
Siebertstraße 3
81675 München / DE
 11  09.12.2021  13.12.2021  ADMISSIBLE
STADA Arzneimittel AG
Stadastrasse 2-18
61118 Bad Vilbel / DE
Opponent's representative
Hamm&Wittkopp Patentanwälte PartmbB
Jungfernstieg 38
20354 Hamburg / DE
 12  10.12.2021  14.12.2021  ADMISSIBLE
Maiwald GmbH
Postfach 33 05 23
80065 München / DE
Opponent's representative
Maiwald GmbH
Elisenhof
Elisenstraße 3
80335 München / DE
Former [2024/04]
Opponent(s)01  10.03.2021  12.03.2021  ADMISSIBLE
Glenmark Pharmaceuticals Europe Ltd
Building 2
Croxley Park
Watford
WD18 8YA / GB
Opponent's representative
Brand Murray Fuller LLP
50 Eastcastle Street
London W1W 8EA / GB
 02  10.03.2021  07.12.2021  ADMISSIBLE
Accord Healthcare Ltd
Sage House
319 Pinner Road
North Harrow Middlesex
HA1 4HF / GB
Opponent's representative
Aera A/S
Niels Hemmingsens Gade 10, 5th Floor
1153 Copenhagen K / DK
 03  10.03.2021  19.11.2021  WITHDRAWN
Teva Pharmaceutical Industries Ltd.
124 Dvora HaNevi'a St.
6944020 Tel Aviv / IL
Opponent's representative
Kraus & Weisert Patentanwälte PartGmbB
Thomas-Wimmer-Ring 15
80539 München / DE
 04  12.03.2021  07.06.2022  WITHDRAWN
EVER Valinject GmbH
Oberburgau 3
4866 Unterach am Attersee / AT
Opponent's representative
SONN Patentanwälte GmbH & Co KG
Riemergasse 14
1010 Wien / AT
 05  12.03.2021  09.12.2021  ADMISSIBLE
Zentiva k.s.
U kabelovny 130
10237 Praha 10 / CZ
Opponent's representative
Greiner, Elisabeth
df-mp Dörries Frank-Molnia & Pohlman
Patentanwälte Rechtsanwälte PartG mbB
Theatinerstraße 16
80333 München / DE
 06  22.03.2021  13.12.2021  ADMISSIBLE
medac Gesellschaft für klinische Spezialpräparate mbH
Theaterstrasse 6
22880 WEDEL / DE
Opponent's representative
Uexküll & Stolberg
Partnerschaft von
Patent- und Rechtsanwälten mbB
Beselerstraße 4
22607 Hamburg / DE
 07  23.03.2021  10.12.2021  ADMISSIBLE
Fresenius Kabi Deutschland GmbH
Else-Kröner-Str. 1
61352 Bad Homburg / DE
 08  31.03.2021  10.09.2021  ADMISSIBLE
Dr. Reddy's Laboratories Ltd./ Betapharm Arzneimittel GmbH
8-2-337 Road No. 3 /Kobelweg 95
Banjara Hills
Hyderabad
500034 Telangana IN / 86156 Augsburg DE / IN
Opponent's representative
Maiwald GmbH
Elisenhof
Elisenstraße 3
80335 München / DE
 09  08.06.2021  10.06.2021  ADMISSIBLE
Generics (U.K.) Limited
Building 4, Trident Place
Mosquito Way
Hatfield Herts AL10 9UL / GB
Opponent's representative
Elkington and Fife LLP
Prospect House
8 Pembroke Road
Sevenoaks, Kent TN13 1XR / GB
 10  03.12.2021  07.12.2021  ADMISSIBLE
Vossius & Partner Patentanwälte Rechtsanwälte mbB
Siebertstrasse 3
81675 München / DE
Opponent's representative
Vossius & Partner Patentanwälte Rechtsanwälte mbB
Siebertstraße 3
81675 München / DE
 11  09.12.2021  13.12.2021  ADMISSIBLE
STADA Arzneimittel AG
Stadastrasse 2-18
61118 Bad Vilbel / DE
Opponent's representative
Hamm&Wittkopp Patentanwälte PartmbB
Jungfernstieg 38
20354 Hamburg / DE
 12  10.12.2021  14.12.2021  ADMISSIBLE
Maiwald GmbH
Postfach 33 05 23
80065 München / DE
Opponent's representative
Maiwald GmbH
Elisenhof
Elisenstraße 3
80335 München / DE
Former [2023/04]
Opponent(s)01  10.03.2021  12.03.2021  ADMISSIBLE
Glenmark Pharmaceuticals Europe Ltd
Building 2
Croxley Park
Watford
WD18 8YA / GB
Opponent's representative
Brand Murray Fuller LLP
50 Eastcastle Street
London W1W 8EA / GB
 02  10.03.2021  07.12.2021  ADMISSIBLE
Accord Healthcare Ltd
Sage House
319 Pinner Road
North Harrow Middlesex
HA1 4HF / GB
Opponent's representative
Aera A/S
Niels Hemmingsens Gade 10, 5th Floor
1153 Copenhagen K / DK
 03  10.03.2021  19.11.2021  WITHDRAWN
Teva Pharmaceutical Industries Ltd.
124 Dvora HaNevi'a St.
6944020 Tel Aviv / IL
Opponent's representative
Lederer & Keller Patentanwälte Partnerschaft mbB
Unsöldstraße 2
80538 München / DE
 04  12.03.2021  07.06.2022  WITHDRAWN
EVER Valinject GmbH
Oberburgau 3
4866 Unterach am Attersee / AT
Opponent's representative
SONN Patentanwälte OG
Riemergasse 14
1010 Wien / AT
 05  12.03.2021  09.12.2021  ADMISSIBLE
Zentiva k.s.
U kabelovny 130
10237 Praha 10 / CZ
Opponent's representative
Greiner, Elisabeth
df-mp Dörries Frank-Molnia & Pohlman
Patentanwälte Rechtsanwälte PartG mbB
Theatinerstraße 16
80333 München / DE
 06  22.03.2021  13.12.2021  ADMISSIBLE
medac Gesellschaft für klinische Spezialpräparate mbH
Theaterstrasse 6
22880 WEDEL / DE
Opponent's representative
Uexküll & Stolberg
Partnerschaft von
Patent- und Rechtsanwälten mbB
Beselerstraße 4
22607 Hamburg / DE
 07  23.03.2021  10.12.2021  ADMISSIBLE
Fresenius Kabi Deutschland GmbH
Else-Kröner-Str. 1
61352 Bad Homburg / DE
 08  31.03.2021  10.09.2021  ADMISSIBLE
Dr. Reddy's Laboratories Ltd./ Betapharm Arzneimittel GmbH
8-2-337 Road No. 3 /Kobelweg 95
Banjara Hills
Hyderabad
500034 Telangana IN / 86156 Augsburg DE / IN
Opponent's representative
Maiwald GmbH
Elisenhof
Elisenstraße 3
80335 München / DE
 09  08.06.2021  10.06.2021  ADMISSIBLE
Generics (U.K.) Limited
Building 4, Trident Place
Mosquito Way
Hatfield Herts AL10 9UL / GB
Opponent's representative
Elkington and Fife LLP
Prospect House
8 Pembroke Road
Sevenoaks, Kent TN13 1XR / GB
 10  03.12.2021  07.12.2021  ADMISSIBLE
Vossius & Partner Patentanwälte Rechtsanwälte mbB
Siebertstrasse 3
81675 München / DE
Opponent's representative
Vossius & Partner Patentanwälte Rechtsanwälte mbB
Siebertstraße 3
81675 München / DE
 11  09.12.2021  13.12.2021  ADMISSIBLE
STADA Arzneimittel AG
Stadastrasse 2-18
61118 Bad Vilbel / DE
Opponent's representative
Hamm&Wittkopp Patentanwälte PartmbB
Jungfernstieg 38
20354 Hamburg / DE
 12  10.12.2021  14.12.2021  ADMISSIBLE
Maiwald GmbH
Postfach 33 05 23
80065 München / DE
Opponent's representative
Maiwald GmbH
Elisenhof
Elisenstraße 3
80335 München / DE
Former [2022/28]
Opponent(s)01  10.03.2021  12.03.2021  ADMISSIBLE
Glenmark Pharmaceuticals Europe Ltd
Building 2
Croxley Park
Watford
WD18 8YA / GB
Opponent's representative
Brand Murray Fuller LLP
50 Eastcastle Street
London W1W 8EA / GB
 02  10.03.2021  07.12.2021  ADMISSIBLE
Accord Healthcare Ltd
Sage House
319 Pinner Road
North Harrow Middlesex
HA1 4HF / GB
Opponent's representative
Aera A/S
Niels Hemmingsens Gade 10, 5th Floor
1153 Copenhagen K / DK
 03  10.03.2021  19.11.2021  WITHDRAWN
Teva Pharmaceutical Industries Ltd.
124 Dvora HaNevi'a St.
6944020 Tel Aviv / IL
Opponent's representative
Lederer & Keller Patentanwälte Partnerschaft mbB
Unsöldstraße 2
80538 München / DE
 04  12.03.2021  07.06.2022  WITHDRAWN
EVER Valinject GmbH
Oberburgau 3
4866 Unterach am Attersee / AT
Opponent's representative
SONN Patentanwälte OG
Riemergasse 14
1010 Wien / AT
 05  12.03.2021  09.12.2021  ADMISSIBLE
Zentiva k.s.
U kabelovny 130
10237 Praha 10 / CZ
Opponent's representative
Greiner, Elisabeth
df-mp Dörries Frank-Molnia & Pohlman
Patentanwälte Rechtsanwälte PartG mbB
Theatinerstraße 16
80333 München / DE
 06  22.03.2021  13.12.2021  ADMISSIBLE
medac Gesellschaft für klinische Spezialpräparate mbH
Theaterstrasse 6
22880 WEDEL / DE
Opponent's representative
Uexküll & Stolberg
Partnerschaft von
Patent- und Rechtsanwälten mbB
Beselerstraße 4
22607 Hamburg / DE
 07  23.03.2021  10.12.2021  ADMISSIBLE
Fresenius Kabi Deutschland GmbH
Else-Kröner-Str. 1
61352 Bad Homburg / DE
 08  31.03.2021  10.09.2021  ADMISSIBLE
Dr. Reddy's Laboratories Ltd./ Betapharm Arzneimittel GmbH
8-2-337 Road No. 3 /Kobelweg 95
Banjara Hills
Hyderabad
500034 Telangana IN / 86156 Augsburg DE / IN
Opponent's representative
Wünsche, Annelie
Maiwald Patentanwalts- und
Rechtsanwaltsgesellschaft mbH
Elisenhof
Elisenstraße 3
80335 München / DE
 09  08.06.2021  10.06.2021  ADMISSIBLE
Generics (U.K.) Limited
Building 4, Trident Place
Mosquito Way
Hatfield Herts AL10 9UL / GB
Opponent's representative
Elkington and Fife LLP
Prospect House
8 Pembroke Road
Sevenoaks, Kent TN13 1XR / GB
 10  03.12.2021  07.12.2021  ADMISSIBLE
Vossius & Partner Patentanwälte Rechtsanwälte mbB
Siebertstrasse 3
81675 München / DE
Opponent's representative
Vossius & Partner Patentanwälte Rechtsanwälte mbB
Siebertstraße 3
81675 München / DE
 11  09.12.2021  13.12.2021  ADMISSIBLE
STADA Arzneimittel AG
Stadastrasse 2-18
61118 Bad Vilbel / DE
Opponent's representative
Hamm&Wittkopp Patentanwälte PartmbB
Jungfernstieg 38
20354 Hamburg / DE
 12  10.12.2021  14.12.2021  ADMISSIBLE
Maiwald Patent- und Rechtsanwaltsgesellschaft mbH
Postfach 33 05 23
80065 München / DE
Opponent's representative
Vos, Derk
Maiwald Patentanwalts- und
Rechtsanwaltsgesellschaft mbH
Elisenhof
Elisenstraße 3
80335 München / DE
Former [2022/19]
Opponent(s)01  10.03.2021  12.03.2021  ADMISSIBLE
Glenmark Pharmaceuticals Europe Ltd
Building 2
Croxley Park
Watford
WD18 8YA / GB
Opponent's representative
Brand Murray Fuller LLP
50 Eastcastle Street
London W1W 8EA / GB
 02  10.03.2021  07.12.2021  ADMISSIBLE
Accord Healthcare Ltd
Sage House
319 Pinner Road
North Harrow Middlesex
HA1 4HF / GB
Opponent's representative
Aera A/S
Niels Hemmingsens Gade 10, 5th Floor
1153 Copenhagen K / DK
 03  10.03.2021  19.11.2021  WITHDRAWN
Teva Pharmaceutical Industries Ltd.
124 Dvora HaNevi'a St.
6944020 Tel Aviv / IL
Opponent's representative
Lederer & Keller Patentanwälte Partnerschaft mbB
Unsöldstraße 2
80538 München / DE
 04  12.03.2021  10.12.2021  ADMISSIBLE
EVER Valinject GmbH
Oberburgau 3
4866 Unterach am Attersee / AT
Opponent's representative
SONN Patentanwälte OG
Riemergasse 14
1010 Wien / AT
 05  12.03.2021  09.12.2021  ADMISSIBLE
Zentiva k.s.
U kabelovny 130
10237 Praha 10 / CZ
Opponent's representative
Greiner, Elisabeth
df-mp Dörries Frank-Molnia & Pohlman
Patentanwälte Rechtsanwälte PartG mbB
Theatinerstraße 16
80333 München / DE
 06  22.03.2021  13.12.2021  ADMISSIBLE
medac Gesellschaft für klinische Spezialpräparate mbH
Theaterstrasse 6
22880 WEDEL / DE
Opponent's representative
Uexküll & Stolberg
Partnerschaft von
Patent- und Rechtsanwälten mbB
Beselerstraße 4
22607 Hamburg / DE
 07  23.03.2021  10.12.2021  ADMISSIBLE
Fresenius Kabi Deutschland GmbH
Else-Kröner-Str. 1
61352 Bad Homburg / DE
 08  31.03.2021  10.09.2021  ADMISSIBLE
Dr. Reddy's Laboratories Ltd./ Betapharm Arzneimittel GmbH
8-2-337 Road No. 3 /Kobelweg 95
Banjara Hills
Hyderabad
500034 Telangana IN / 86156 Augsburg DE / IN
Opponent's representative
Wünsche, Annelie
Maiwald Patentanwalts- und
Rechtsanwaltsgesellschaft mbH
Elisenhof
Elisenstraße 3
80335 München / DE
 09  08.06.2021  10.06.2021  ADMISSIBLE
Generics (U.K.) Limited
Building 4, Trident Place
Mosquito Way
Hatfield Herts AL10 9UL / GB
Opponent's representative
Elkington and Fife LLP
Prospect House
8 Pembroke Road
Sevenoaks, Kent TN13 1XR / GB
 10  03.12.2021  07.12.2021  ADMISSIBLE
Vossius & Partner Patentanwälte Rechtsanwälte mbB
Siebertstrasse 3
81675 München / DE
Opponent's representative
Vossius & Partner Patentanwälte Rechtsanwälte mbB
Siebertstraße 3
81675 München / DE
 11  09.12.2021  13.12.2021  ADMISSIBLE
STADA Arzneimittel AG
Stadastrasse 2-18
61118 Bad Vilbel / DE
Opponent's representative
Hamm&Wittkopp Patentanwälte PartmbB
Jungfernstieg 38
20354 Hamburg / DE
 12  10.12.2021  14.12.2021  ADMISSIBLE
Maiwald Patent- und Rechtsanwaltsgesellschaft mbH
Postfach 33 05 23
80065 München / DE
Opponent's representative
Vos, Derk
Maiwald Patentanwalts- und
Rechtsanwaltsgesellschaft mbH
Elisenhof
Elisenstraße 3
80335 München / DE
Former [2022/03]
Opponent(s)01  10.03.2021  12.03.2021  ADMISSIBLE
Glenmark Pharmaceuticals Europe Ltd
Building 2
Croxley Park
Watford
WD18 8YA / GB
Opponent's representative
Brand Murray Fuller LLP
50 Eastcastle Street
London W1W 8EA / GB
 02  10.03.2021  07.12.2021  ADMISSIBLE
Accord Healthcare Ltd
Sage House
319 Pinner Road
North Harrow Middlesex
HA1 4HF / GB
Opponent's representative
Aera A/S
Niels Hemmingsens Gade 10, 5th Floor
1153 Copenhagen / DK
 03  10.03.2021  19.11.2021  WITHDRAWN
Teva Pharmaceutical Industries Ltd.
124 Dvora HaNevi'a St.
6944020 Tel Aviv / IL
Opponent's representative
Lederer & Keller Patentanwälte Partnerschaft mbB
Unsöldstraße 2
80538 München / DE
 04  12.03.2021  10.12.2021  ADMISSIBLE
EVER Valinject GmbH
Oberburgau 3
4866 Unterach am Attersee / AT
Opponent's representative
SONN Patentanwälte OG
Riemergasse 14
1010 Wien / AT
 05  12.03.2021  09.12.2021  ADMISSIBLE
Zentiva k.s.
U kabelovny 130
10237 Praha 10 / CZ
Opponent's representative
Greiner, Elisabeth
df-mp Dörries Frank-Molnia & Pohlman
Patentanwälte Rechtsanwälte PartG mbB
Theatinerstraße 16
80333 München / DE
 06  22.03.2021  13.12.2021  ADMISSIBLE
medac Gesellschaft für klinische Spezialpräparate mbH
Theaterstrasse 6
22880 WEDEL / DE
Opponent's representative
Uexküll & Stolberg
Partnerschaft von
Patent- und Rechtsanwälten mbB
Beselerstraße 4
22607 Hamburg / DE
 07  23.03.2021  10.12.2021  ADMISSIBLE
Fresenius Kabi Deutschland GmbH
Else-Kröner-Str. 1
61352 Bad Homburg / DE
 08  31.03.2021  10.09.2021  ADMISSIBLE
Dr. Reddy's Laboratories Ltd./ Betapharm Arzneimittel GmbH
8-2-337 Road No. 3 /Kobelweg 95
Banjara Hills
Hyderabad
500034 Telangana IN / 86156 Augsburg DE / IN
Opponent's representative
Wünsche, Annelie
Maiwald Patentanwalts- und
Rechtsanwaltsgesellschaft mbH
Elisenhof
Elisenstraße 3
80335 München / DE
 09  08.06.2021  10.06.2021  ADMISSIBLE
Generics (U.K.) Limited
Building 4, Trident Place
Mosquito Way
Hatfield Herts AL10 9UL / GB
Opponent's representative
Elkington and Fife LLP
Prospect House
8 Pembroke Road
Sevenoaks, Kent TN13 1XR / GB
 10  03.12.2021  07.12.2021  ADMISSIBLE
Vossius & Partner Patentanwälte Rechtsanwälte mbB
Siebertstrasse 3
81675 München / DE
Opponent's representative
Vossius & Partner Patentanwälte Rechtsanwälte mbB
Siebertstraße 3
81675 München / DE
 11  09.12.2021  13.12.2021  ADMISSIBLE
STADA Arzneimittel AG
Stadastrasse 2-18
61118 Bad Vilbel / DE
Opponent's representative
Hamm&Wittkopp Patentanwälte PartmbB
Jungfernstieg 38
20354 Hamburg / DE
 12  10.12.2021  14.12.2021  ADMISSIBLE
Maiwald Patent- und Rechtsanwaltsgesellschaft mbH
Postfach 33 05 23
80065 München / DE
Opponent's representative
Vos, Derk
Maiwald Patentanwalts- und
Rechtsanwaltsgesellschaft mbH
Elisenhof
Elisenstraße 3
80335 München / DE
Former [2022/02]
Opponent(s)01  10.03.2021  12.03.2021  ADMISSIBLE
Glenmark Pharmaceuticals Europe Ltd
Building 2
Croxley Park
Watford
WD18 8YA / GB
Opponent's representative
Brand Murray Fuller LLP
50 Eastcastle Street
London W1W 8EA / GB
 02  10.03.2021  07.12.2021  ADMISSIBLE
Accord Healthcare Ltd
Sage House
319 Pinner Road
North Harrow Middlesex
HA1 4HF / GB
Opponent's representative
Aera A/S
Niels Hemmingsens Gade 10, 5th Floor
1153 Copenhagen / DK
 03  10.03.2021  19.11.2021  WITHDRAWN
Teva Pharmaceutical Industries Ltd.
124 Dvora HaNevi'a St.
6944020 Tel Aviv / IL
Opponent's representative
Lederer & Keller Patentanwälte Partnerschaft mbB
Unsöldstraße 2
80538 München / DE
 04  12.03.2021   
EVER Valinject GmbH
Oberburgau 3
4866 Unterach am Attersee / AT
Opponent's representative
SONN Patentanwälte OG
Riemergasse 14
1010 Wien / AT
 05  12.03.2021  09.12.2021  ADMISSIBLE
Zentiva k.s.
U kabelovny 130
10237 Praha 10 / CZ
Opponent's representative
Greiner, Elisabeth
df-mp Dörries Frank-Molnia & Pohlman
Patentanwälte Rechtsanwälte PartG mbB
Theatinerstraße 16
80333 München / DE
 06  22.03.2021   
medac Gesellschaft für klinische Spezialpräparate mbH
Theaterstrasse 6
22880 WEDEL / DE
Opponent's representative
Uexküll & Stolberg
Partnerschaft von
Patent- und Rechtsanwälten mbB
Beselerstraße 4
22607 Hamburg / DE
 07  23.03.2021   
Fresenius Kabi Deutschland GmbH
Else-Kröner-Str. 1
61352 Bad Homburg / DE
 08  31.03.2021  10.09.2021  ADMISSIBLE
Dr. Reddy's Laboratories Ltd./ Betapharm Arzneimittel GmbH
8-2-337 Road No. 3 /Kobelweg 95
Banjara Hills
Hyderabad
500034 Telangana IN / 86156 Augsburg DE / IN
Opponent's representative
Wünsche, Annelie
Maiwald Patentanwalts- und
Rechtsanwaltsgesellschaft mbH
Elisenhof
Elisenstraße 3
80335 München / DE
 09  08.06.2021  10.06.2021  ADMISSIBLE
Generics (U.K.) Limited
Building 4, Trident Place
Mosquito Way
Hatfield Herts AL10 9UL / GB
Opponent's representative
Elkington and Fife LLP
Prospect House
8 Pembroke Road
Sevenoaks, Kent TN13 1XR / GB
 10  03.12.2021  07.12.2021  ADMISSIBLE
Vossius & Partner Patentanwälte Rechtsanwälte mbB
Siebertstrasse 3
81675 München / DE
Opponent's representative
Vossius & Partner Patentanwälte Rechtsanwälte mbB
Siebertstraße 3
81675 München / DE
Former [2021/52]
Opponent(s)01  10.03.2021  12.03.2021  ADMISSIBLE
Glenmark Pharmaceuticals Europe Ltd
Building 2
Croxley Park
Watford
WD18 8YA / GB
Opponent's representative
Brand Murray Fuller LLP
50 Eastcastle Street
London W1W 8EA / GB
 02  10.03.2021   
Accord Healthcare Ltd
Sage House
319 Pinner Road
North Harrow Middlesex
HA1 4HF / GB
Opponent's representative
Aera A/S
Niels Hemmingsens Gade 10, 5th Floor
1153 Copenhagen / DK
 03  10.03.2021  19.11.2021  WITHDRAWN
Teva Pharmaceutical Industries Ltd.
124 Dvora HaNevi'a St.
6944020 Tel Aviv / IL
Opponent's representative
Lederer & Keller Patentanwälte Partnerschaft mbB
Unsöldstraße 2
80538 München / DE
 04  12.03.2021   
EVER Valinject GmbH
Oberburgau 3
4866 Unterach am Attersee / AT
Opponent's representative
SONN Patentanwälte OG
Riemergasse 14
1010 Wien / AT
 05  12.03.2021   
Zentiva k.s.
U kabelovny 130
10237 Praha 10 / CZ
Opponent's representative
Greiner, Elisabeth
df-mp Dörries Frank-Molnia & Pohlman
Patentanwälte Rechtsanwälte PartG mbB
Theatinerstraße 16
80333 München / DE
 06  22.03.2021   
medac Gesellschaft für klinische Spezialpräparate mbH
Theaterstrasse 6
22880 WEDEL / DE
Opponent's representative
Uexküll & Stolberg
Partnerschaft von
Patent- und Rechtsanwälten mbB
Beselerstraße 4
22607 Hamburg / DE
 07  23.03.2021   
Fresenius Kabi Deutschland GmbH
Else-Kröner-Str. 1
61352 Bad Homburg / DE
 08  31.03.2021  10.09.2021  ADMISSIBLE
Dr. Reddy's Laboratories Ltd./ Betapharm Arzneimittel GmbH
8-2-337 Road No. 3 /Kobelweg 95
Banjara Hills
Hyderabad
500034 Telangana IN / 86156 Augsburg DE / IN
Opponent's representative
Wünsche, Annelie
Maiwald Patentanwalts- und
Rechtsanwaltsgesellschaft mbH
Elisenhof
Elisenstraße 3
80335 München / DE
 09  08.06.2021  10.06.2021  ADMISSIBLE
Generics (U.K.) Limited
Building 4, Trident Place
Mosquito Way
Hatfield Herts AL10 9UL / GB
Opponent's representative
Elkington and Fife LLP
Prospect House
8 Pembroke Road
Sevenoaks, Kent TN13 1XR / GB
Former [2021/28]
Opponent(s)01  10.03.2021  12.03.2021  ADMISSIBLE
Glenmark Pharmaceuticals Europe Ltd
Building 2
Croxley Park
Watford
WD18 8YA / GB
Opponent's representative
Brand Murray Fuller LLP
50 Eastcastle Street
London W1W 8EA / GB
 02  10.03.2021   
Accord Healthcare Ltd
Sage House
319 Pinner Road
North Harrow Middlesex
HA1 4HF / GB
Opponent's representative
Aera A/S
Niels Hemmingsens Gade 10, 5th Floor
1153 Copenhagen / DK
 03  10.03.2021  12.03.2021  ADMISSIBLE
Teva Pharmaceutical Industries Ltd.
5 Basel Street
Petach Tikva 49131 / IL
Opponent's representative
Lederer & Keller Patentanwälte Partnerschaft mbB
Unsöldstraße 2
80538 München / DE
 04  12.03.2021   
EVER Valinject GmbH
Oberburgau 3
4866 Unterach am Attersee / AT
Opponent's representative
Sonn & Partner Patentanwälte
Riemergasse 14
1010 Wien / AT
 05  12.03.2021   
Zentiva k.s.
U kabelovny 130
10237 Praha 10 / CZ
Opponent's representative
Greiner, Elisabeth
df-mp Dörries Frank-Molnia & Pohlman
Patentanwälte Rechtsanwälte PartG mbB
Theatinerstraße 16
80333 München / DE
 06  22.03.2021   
medac Gesellschaft für klinische Spezialpräparate mbH
Theaterstrasse 6
22880 WEDEL / DE
Opponent's representative
Uexküll & Stolberg
Partnerschaft von
Patent- und Rechtsanwälten mbB
Beselerstraße 4
22607 Hamburg / DE
 07  23.03.2021   
Fresenius Kabi Deutschland GmbH
Else-Kröner-Str. 1
61352 Bad Homburg / DE
 08  31.03.2021   
Dr. Reddy's Laboratories Ltd./ Betapharm Arzneimittel GmbH
8-2-337 Road No. 3 /Kobelweg 95
Banjara Hills
Hyderabad
500034 Telangana IN / 86156 Augsburg DE / IN
Opponent's representative
Wünsche, Annelie
Maiwald Patentanwalts- und
Rechtsanwaltsgesellschaft mbH
Elisenhof
Elisenstraße 3
80335 München / DE
 09  08.06.2021  10.06.2021  ADMISSIBLE
Generics (U.K.) Limited
Building 4, Trident Place
Mosquito Way
Hatfield Herts AL10 9UL / GB
Opponent's representative
Elkington and Fife LLP
Prospect House
8 Pembroke Road
Sevenoaks, Kent TN13 1XR / GB
Former [2021/19]
Opponent(s)01  10.03.2021  12.03.2021  ADMISSIBLE
Glenmark Pharmaceuticals Europe Ltd
Building 2
Croxley Park
Watford
WD18 8YA / GB
Opponent's representative
Brand Murray Fuller LLP
50 Eastcastle Street
London W1W 8EA / GB
 02  10.03.2021   
Accord Healthcare Ltd
Sage House
319 Pinner Road
North Harrow Middlesex
HA1 4HF / GB
Opponent's representative
Aera A/S
Gammel Kongevej 60, 18th floor
1850 Frederiksberg C / DK
 03  10.03.2021  12.03.2021  ADMISSIBLE
Teva Pharmaceutical Industries Ltd.
5 Basel Street
Petach Tikva 49131 / IL
Opponent's representative
Lederer & Keller Patentanwälte Partnerschaft mbB
Unsöldstraße 2
80538 München / DE
 04  12.03.2021   
EVER Valinject GmbH
Oberburgau 3
4866 Unterach am Attersee / AT
Opponent's representative
Sonn & Partner Patentanwälte
Riemergasse 14
1010 Wien / AT
 05  12.03.2021   
Zentiva k.s.
U kabelovny 130
10237 Praha 10 / CZ
Opponent's representative
Greiner, Elisabeth
df-mp Dörries Frank-Molnia & Pohlman
Patentanwälte Rechtsanwälte PartG mbB
Theatinerstraße 16
80333 München / DE
 06  22.03.2021   
medac Gesellschaft für klinische Spezialpräparate mbH
Theaterstrasse 6
22880 WEDEL / DE
Opponent's representative
Uexküll & Stolberg
Partnerschaft von
Patent- und Rechtsanwälten mbB
Beselerstraße 4
22607 Hamburg / DE
 07  23.03.2021   
Fresenius Kabi Deutschland GmbH
Else-Kröner-Str. 1
61352 Bad Homburg / DE
 08  31.03.2021   
Dr. Reddy's Laboratories Ltd./ Betapharm Arzneimittel GmbH
8-2-337 Road No. 3 /Kobelweg 95
Banjara Hills
Hyderabad
500034 Telangana IN / 86156 Augsburg DE / IN
Opponent's representative
Wünsche, Annelie
Maiwald Patentanwalts- und
Rechtsanwaltsgesellschaft mbH
Elisenhof
Elisenstraße 3
80335 München / DE
Former [2021/17]
Opponent(s)01  10.03.2021  12.03.2021  ADMISSIBLE
Glenmark Pharmaceuticals Europe Ltd
Building 2
Croxley Park
Watford
WD18 8YA / GB
Opponent's representative
Brand Murray Fuller LLP
50 Eastcastle Street
London W1W 8EA / GB
 02  10.03.2021   
Accord Healthcare Ltd
Sage House
319 Pinner Road
North Harrow Middlesex
HA1 4HF / GB
Opponent's representative
Aera A/S
Gammel Kongevej 60, 18th floor
1850 Frederiksberg C / DK
 03  10.03.2021  12.03.2021  ADMISSIBLE
Teva Pharmaceutical Industries Ltd.
5 Basel Street
Petach Tikva 49131 / IL
Opponent's representative
Lederer & Keller Patentanwälte Partnerschaft mbB
Unsöldstraße 2
80538 München / DE
 04  12.03.2021   
EVER Valinject GmbH
Oberburgau 3
4866 Unterach am Attersee / AT
Opponent's representative
Sonn & Partner Patentanwälte
Riemergasse 14
1010 Wien / AT
 05  12.03.2021   
Zentiva k.s.
U kabelovny 130
10237 Praha 10 / CZ
Opponent's representative
Greiner, Elisabeth
df-mp Dörries Frank-Molnia & Pohlman
Patentanwälte Rechtsanwälte PartG mbB
Theatinerstraße 16
80333 München / DE
 06  22.03.2021   
medac Gesellschaft für klinische Spezialpräparate mbH
Theaterstrasse 6
22880 WEDEL / DE
Opponent's representative
Uexküll & Stolberg
Partnerschaft von
Patent- und Rechtsanwälten mbB
Beselerstraße 4
22607 Hamburg / DE
 07  23.03.2021   
Fresenius Kabi Deutschland GmbH
Else-Kröner-Str. 1
61352 Bad Homburg / DE
Former [2021/16]
Opponent(s)01  10.03.2021  12.03.2021  ADMISSIBLE
Glenmark Pharmaceuticals Europe Ltd
Building 2
Croxley Park
Watford
WD18 8YA / GB
Opponent's representative
Brand Murray Fuller LLP
50 Eastcastle Street
London W1W 8EA / GB
 02  10.03.2021   
Accord Healthcare Ltd
Sage House
319 Pinner Road
North Harrow Middlesex
HA1 4HF / GB
Opponent's representative
Aera A/S
Gammel Kongevej 60, 18th floor
1850 Frederiksberg C / DK
 03  10.03.2021  12.03.2021  ADMISSIBLE
Teva Pharmaceutical Industries Ltd.
5 Basel Street
Petach Tikva 49131 / IL
Opponent's representative
Lederer & Keller Patentanwälte Partnerschaft mbB
Unsöldstraße 2
80538 München / DE
 04  12.03.2021   
EVER Valinject GmbH
Oberburgau 3
4866 Unterach am Attersee / AT
Opponent's representative
Sonn & Partner Patentanwälte
Riemergasse 14
1010 Wien / AT
 05  12.03.2021   
Zentiva k.s.
U kabelovny 130
10237 Praha 10 / CZ
Opponent's representative
Greiner, Elisabeth
df-mp Dörries Frank-Molnia & Pohlman
Patentanwälte Rechtsanwälte PartG mbB
Theatinerstraße 16
80333 München / DE
Former [2021/15]
Opponent(s)01  10.03.2021   
Glenmark Pharmaceuticals Europe Ltd
Building 2, 1st Floor
Croxley Green Business Park
Watford
Hertfordshire WD18 8YA / GB
Opponent's representative
Brand Murray Fuller LLP
50 Eastcastle Street
London W1W 8EA / GB
 02  10.03.2021   
Accord Healthcare Ltd
Sage House
319 Pinner Road
North Harrow Middlesex
HA1 4HF / GB
Opponent's representative
Aera A/S
Gammel Kongevej 60, 18th floor
1850 Frederiksberg C / DK
 03  10.03.2021   
Teva Pharmaceutical Industries Ltd.
5 Basel Street
Petach Tikva 49131 / IL
Opponent's representative
Lederer & Keller Patentanwälte Partnerschaft mbB
Unsöldstraße 2
80538 München / DE
18.03.2021No. 02: Notification indicating deficiencies in the notice of opposition
18.03.2021No. 04: Notification indicating deficiencies in the notice of opposition
18.03.2021No. 05: Notification indicating deficiencies in the notice of opposition
26.03.2021No. 06: Notification indicating deficiencies in the notice of opposition
26.03.2021No. 07: Notification indicating deficiencies in the notice of opposition
04.05.2021No. 02: Reply to notification indicating deficiencies in the notice of opposition
07.12.2021No. 05: Reply to notification indicating deficiencies in the notice of opposition
09.12.2021No. 07: Reply to notification indicating deficiencies in the notice of opposition
10.12.2021No. 04: Reply to notification indicating deficiencies in the notice of opposition
10.12.2021No. 06: Reply to notification indicating deficiencies in the notice of opposition
22.12.2021Invitation to proprietor to file observations on the notice of opposition
28.04.2022Reply of patent proprietor to notice(s) of opposition
24.08.2023Cancellation of oral proceeding that was planned for 12.09.2023
12.09.2023Date of oral proceedings
13.12.2023Date of oral proceedings
25.01.2024Despatch of minutes of oral proceedings
25.01.2024Date of despatch of rejection of opposition
03.06.2025Legal effect of rejection of opposition [2025/43]
Appeal following opposition23.02.2024Appeal received No.  T0136/24
23.02.2024Payment of appeal fee
27.05.2024Statement of grounds filed
03.06.2025Result of appeal procedure: appeal of the opponent was rejected
15.09.2025Despatch of the decision of the Board of Appeal
26.01.2024Appeal received No.  T0136/24
26.01.2024Payment of appeal fee
27.05.2024Statement of grounds filed
03.06.2025Result of appeal procedure: appeal of the opponent was rejected
15.09.2025Despatch of the decision of the Board of Appeal
23.02.2024Appeal received No.  T0136/24
23.02.2024Payment of appeal fee
24.05.2024Statement of grounds filed
03.06.2025Result of appeal procedure: appeal of the opponent was rejected
15.09.2025Despatch of the decision of the Board of Appeal
15.02.2024Appeal received No.  T0136/24
15.02.2024Payment of appeal fee
24.05.2024Statement of grounds filed
03.06.2025Result of appeal procedure: appeal of the opponent was rejected
15.09.2025Despatch of the decision of the Board of Appeal
15.01.2024Appeal received No.  T0136/24
15.01.2024Payment of appeal fee
24.05.2024Statement of grounds filed
03.06.2025Result of appeal procedure: appeal of the opponent was rejected
15.09.2025Despatch of the decision of the Board of Appeal
12.02.2024Appeal received No.  T0136/24
12.02.2024Payment of appeal fee
23.05.2024Statement of grounds filed
03.06.2025Result of appeal procedure: appeal of the opponent was rejected
15.09.2025Despatch of the decision of the Board of Appeal
07.02.2024Appeal received No.  T0136/24
07.02.2024Payment of appeal fee
22.05.2024Statement of grounds filed
03.06.2025Result of appeal procedure: appeal of the opponent was rejected
15.09.2025Despatch of the decision of the Board of Appeal
22.03.2024Appeal received No.  T0136/24
22.03.2024Payment of appeal fee
21.05.2024Statement of grounds filed
03.06.2025Result of appeal procedure: appeal of the opponent was rejected
15.09.2025Despatch of the decision of the Board of Appeal
22.02.2024Appeal received No.  T0136/24
22.02.2024Payment of appeal fee
21.05.2024Statement of grounds filed
03.06.2025Result of appeal procedure: appeal of the opponent was rejected
15.09.2025Despatch of the decision of the Board of Appeal
02.02.2024Appeal received No.  T0136/24
02.02.2024Payment of appeal fee
29.04.2024Statement of grounds filed
03.06.2025Result of appeal procedure: appeal of the opponent was rejected
15.09.2025Despatch of the decision of the Board of Appeal
02.06.2025Date of oral proceedings
Petition(s) for review:14.10.2025Petition for review received
 Number:  R0018/25
 for appeal No.  T0136/24-3304
 Petitioner:  OP09
14.11.2025Petition for review received
 Number:  R0020/25
 for appeal No.  T0136/24-3304
 Petitioner:  OP01
17.11.2025Petition for review received
 Number:  R0021/25
 for appeal No.  T0136/24-3304
 Petitioner:  OP05
Fees paidRenewal fee
11.10.2012Renewal fee patent year 03
14.10.2013Renewal fee patent year 04
14.10.2014Renewal fee patent year 05
12.10.2015Renewal fee patent year 06
11.10.2016Renewal fee patent year 07
11.10.2017Renewal fee patent year 08
11.10.2018Renewal fee patent year 09
15.10.2019Renewal fee patent year 10
14.10.2020Renewal fee patent year 11
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Licence(s)ID:01 00/not-exclusive
For:FR
Licencee:Sanofi Winthrop Industrie
20 Avenue Raymond Aron
92160 Antony / FR
Date:07.02.2021
ID:01 01/not-exclusive
For:FR
Licencee:Sanofi-Aventis France
82 Avenue Raspail
94250 Gentilly / FR
Date:07.02.2021
[2021/15]
Former [2012/36]deleted
[2021/15]
Lapses during opposition  TooltipHU27.10.2010
AL10.03.2021
CY10.03.2021
CZ10.03.2021
EE10.03.2021
FI10.03.2021
HR10.03.2021
LT10.03.2021
LV10.03.2021
MC10.03.2021
MK10.03.2021
MT10.03.2021
RO10.03.2021
RS10.03.2021
SI10.03.2021
SK10.03.2021
SM10.03.2021
TR10.03.2021
BG10.06.2021
NO10.06.2021
IS10.07.2021
IE27.10.2021
LU27.10.2021
[2024/41]
Former [2024/29]HU27.10.2010
AL10.03.2021
CY10.03.2021
CZ10.03.2021
EE10.03.2021
FI10.03.2021
HR10.03.2021
LT10.03.2021
LV10.03.2021
MC10.03.2021
MK10.03.2021
RO10.03.2021
RS10.03.2021
SI10.03.2021
SK10.03.2021
SM10.03.2021
TR10.03.2021
BG10.06.2021
NO10.06.2021
IS10.07.2021
IE27.10.2021
LU27.10.2021
Former [2024/22]HU27.10.2010
AL10.03.2021
CY10.03.2021
CZ10.03.2021
EE10.03.2021
FI10.03.2021
HR10.03.2021
LT10.03.2021
LV10.03.2021
MC10.03.2021
MK10.03.2021
RO10.03.2021
RS10.03.2021
SI10.03.2021
SK10.03.2021
SM10.03.2021
BG10.06.2021
NO10.06.2021
IS10.07.2021
IE27.10.2021
LU27.10.2021
Former [2023/29]HU27.10.2010
AL10.03.2021
CY10.03.2021
CZ10.03.2021
EE10.03.2021
FI10.03.2021
HR10.03.2021
LT10.03.2021
LV10.03.2021
MC10.03.2021
RO10.03.2021
RS10.03.2021
SI10.03.2021
SK10.03.2021
SM10.03.2021
BG10.06.2021
NO10.06.2021
IS10.07.2021
IE27.10.2021
LU27.10.2021
Former [2023/24]AL10.03.2021
CY10.03.2021
CZ10.03.2021
EE10.03.2021
FI10.03.2021
HR10.03.2021
LT10.03.2021
LV10.03.2021
MC10.03.2021
RO10.03.2021
RS10.03.2021
SI10.03.2021
SK10.03.2021
SM10.03.2021
BG10.06.2021
NO10.06.2021
IS10.07.2021
IE27.10.2021
LU27.10.2021
Former [2022/48]AL10.03.2021
CZ10.03.2021
EE10.03.2021
FI10.03.2021
HR10.03.2021
LT10.03.2021
LV10.03.2021
MC10.03.2021
RO10.03.2021
RS10.03.2021
SI10.03.2021
SK10.03.2021
SM10.03.2021
BG10.06.2021
NO10.06.2021
IS10.07.2021
IE27.10.2021
LU27.10.2021
Former [2022/35]AL10.03.2021
CZ10.03.2021
EE10.03.2021
FI10.03.2021
HR10.03.2021
LT10.03.2021
LV10.03.2021
MC10.03.2021
RO10.03.2021
RS10.03.2021
SI10.03.2021
SK10.03.2021
SM10.03.2021
BG10.06.2021
NO10.06.2021
IS10.07.2021
LU27.10.2021
Former [2022/33]AL10.03.2021
CZ10.03.2021
EE10.03.2021
FI10.03.2021
HR10.03.2021
LT10.03.2021
LV10.03.2021
MC10.03.2021
RO10.03.2021
RS10.03.2021
SI10.03.2021
SK10.03.2021
SM10.03.2021
BG10.06.2021
NO10.06.2021
IS10.07.2021
Former [2022/23]AL10.03.2021
CZ10.03.2021
EE10.03.2021
FI10.03.2021
HR10.03.2021
LT10.03.2021
LV10.03.2021
RO10.03.2021
RS10.03.2021
SI10.03.2021
SK10.03.2021
SM10.03.2021
BG10.06.2021
NO10.06.2021
IS10.07.2021
Former [2022/13]AL10.03.2021
CZ10.03.2021
EE10.03.2021
FI10.03.2021
HR10.03.2021
LT10.03.2021
LV10.03.2021
RO10.03.2021
RS10.03.2021
SI10.03.2021
SK10.03.2021
SM10.03.2021
BG10.06.2021
NO10.06.2021
IS29.12.2021
Former [2022/10]AL10.03.2021
CZ10.03.2021
EE10.03.2021
FI10.03.2021
HR10.03.2021
LT10.03.2021
LV10.03.2021
RO10.03.2021
RS10.03.2021
SK10.03.2021
SM10.03.2021
BG10.06.2021
NO10.06.2021
IS29.12.2021
Former [2022/07]AL10.03.2021
CZ10.03.2021
EE10.03.2021
FI10.03.2021
HR10.03.2021
LT10.03.2021
LV10.03.2021
RO10.03.2021
RS10.03.2021
SK10.03.2021
SM10.03.2021
BG10.06.2021
NO10.06.2021
IS10.07.2021
Former [2021/51]CZ10.03.2021
EE10.03.2021
FI10.03.2021
HR10.03.2021
LT10.03.2021
LV10.03.2021
RO10.03.2021
RS10.03.2021
SK10.03.2021
SM10.03.2021
BG10.06.2021
NO10.06.2021
IS10.07.2021
Former [2021/50]CZ10.03.2021
EE10.03.2021
FI10.03.2021
HR10.03.2021
LT10.03.2021
LV10.03.2021
RO10.03.2021
RS10.03.2021
SK10.03.2021
SM10.03.2021
BG10.06.2021
NO10.06.2021
Former [2021/48]CZ10.03.2021
EE10.03.2021
FI10.03.2021
HR10.03.2021
LT10.03.2021
LV10.03.2021
RS10.03.2021
SM10.03.2021
BG10.06.2021
NO10.06.2021
Former [2021/46]FI10.03.2021
HR10.03.2021
LT10.03.2021
LV10.03.2021
RS10.03.2021
SM10.03.2021
BG10.06.2021
NO10.06.2021
Former [2021/37]FI10.03.2021
HR10.03.2021
LT10.03.2021
LV10.03.2021
RS10.03.2021
BG10.06.2021
NO10.06.2021
Former [2021/36]FI10.03.2021
HR10.03.2021
LT10.03.2021
BG10.06.2021
NO10.06.2021
Former [2021/35]FI10.03.2021
HR10.03.2021
LT10.03.2021
NO10.06.2021
Former [2021/33]FI10.03.2021
LT10.03.2021
NO10.06.2021
Cited inInternational search[Y] US2005065138  (DIDIER ERIC et al.)
 [XP] EP2177630  (ROUSSY INST GUSTAVE et al.)
 [XY]   MITA, ALAIN C. ET AL: "Phase I and Pharmacokinetic Study of XRP6258 (RPR 116258A), a Novel Taxane, Administered as a 1-Hour Infusion Every 3 Weeks in Patients with Advanced Solid Tumors", CLINICAL CANCER RESEARCH , 15(2), 723-730 CODEN: CCREF4; ISSN: 1078-0432, 2009, XP002623316

DOI:   http://dx.doi.org/10.1158/1078-0432.ccr-08-0596
 [Y]   TANNOCK IAN F ET AL: "Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.", THE NEW ENGLAND JOURNAL OF MEDICINE 7 OCT 2004 LNKD- PUBMED:15470213, vol. 351, no. 15, 7 October 2004 (2004-10-07), pages 1502 - 1512, XP002623317, ISSN: 1533-4406

DOI:   http://dx.doi.org/10.1056/NEJMoa040720
 [Y]   SOUTHWEST ONCOLOGY GROUP ET AL: "Quality of life and pain in advanced stage prostate cancer: results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone.", JOURNAL OF CLINICAL ONCOLOGY : OFFICIAL JOURNAL OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY 20 JUN 2006 LNKD- PUBMED:16782921, vol. 24, no. 18, 20 June 2006 (2006-06-20), pages 2828 - 2835, XP002623318, ISSN: 1527-7755

DOI:   http://dx.doi.org/10.1200/JCO.2005.04.8207
 [XP]   FOR THE TROPIC INVESTIGATORS ET AL: "Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial", LANCET THE, LANCET LIMITED. LONDON, GB, vol. 376, no. 9747, 2 October 2010 (2010-10-02), pages 1147 - 1154, XP027490891, ISSN: 0140-6736, [retrieved on 20101002]

DOI:   http://dx.doi.org/10.1016/S0140-6736(10)61389-X
 [XP]   GALSKY, MATTHEW D. ET AL: "Cabazitaxel", NATURE REVIEWS DRUG DISCOVERY , 9(9), 677-678 CODEN: NRDDAG; ISSN: 1474-1776, 2010, XP002623319

DOI:   http://dx.doi.org/10.1038/nrd3254
by applicantWO9630355
 EP0817779
 US5847170
 WO2005002846
   CA CANCER J. CLIN., vol. 55, 2005, pages 74 - 108
   CA CANCER J. CLIN., vol. 52, May 2002 (2002-05-01), pages 154 - 179
   CA CANCER J. CLIN., vol. 50, November 2000 (2000-11-01), pages 349 - 375
   "Advances in Prostate Cancer Chemotherapy: A New Era Begins CA Cancer", J. CLIN., vol. 55, September 2005 (2005-09-01), pages 300 - 318
   DRUG RESISTANCE UPDATES, vol. 4, no. 1, 2001, pages 3 - 8
   J. CLIN. ONC., vol. 17, no. 3, 1999, pages 1061 - 1070
   J. PHARM. SCI., vol. 64, no. 8, 1975, pages 1269 - 1288
   MELZACK R., PAIN, vol. 1, 1975, pages 277 - 99
otherEP2493466
   "JEVTANA 60 mg Konzentrat und Lsungsmittel zur Herstellung einer Infusionlsung", SANOFI GENZYME FACHINFORMATION, 1 April 2017 (2017-04-01), pages 1 - 11, XP055617507
   "XRP6258 Plus Prednisone Compared to Mitoxantrone Plus Prednisone in Hormone Refractory Metastatic Prostate Cancer", no. NCT00417079, 8 December 2009 (2009-12-08), XP055609984, Retrieved from the Internet
   "XRP6258 Plus Prednisone Compared to Mitoxantrone Plus Prednisone in Hormone Refractory Metastatic Prostate Cancer", no. NCT00417079, 3 June 2010 (2010-06-03), XP055609986, Retrieved from the Internet
   H-J LENZ: "Management and Preparedness for Infusion and Hypersensitivity Reactions", THE ONCOLOGIST, vol. 12, pages 601 - 609, XP055609965

DOI:   http://dx.doi.org/10.1634/theoncologist.12-5-601
   X. PIVOT ET AL.: "A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients", ANNALS OF ONCOLOGY, vol. 19, 2008, pages 1547 - 1552, XP002551475

DOI:   http://dx.doi.org/10.1093/annonc/mdn171
   ANONYMOUS: "XRP6258 Plus Prednisone Compared to Mitoxantrone Plus Prednisone in Hormone Refractory Metastatic Prostate Cancer / ClinicalTrials.gov", INTERNET ARCHIVE WAYBACK MACHINE, 23 October 2008 (2008-10-23), pages 3pp, XP055712286
   BEARDSLEY ET AL.: "Systemic therapy after first-line docetaxel in metastatic castration-resistant prostate cancer", CURR OPIN SUPPORT PALLIAT CARE, vol. 2, 2008, pages 161 - 166, XP009149037

DOI:   http://dx.doi.org/10.1097/SPC.0b013e32830c48a3
   GALLETTI ET AL.: "Paclitaxel And Docetaxel Resistance: Molecular Mechanisms and Development of New Generation Taxanes", CHEMMEDCHEM, vol. 2, 2007, pages 920 - 942, XP055710948
   ATTARD ET AL.: "Update on tubulin-binding agents", PATHOLOGIE ET BIOLOGIE,, vol. 54, 2006, pages 72 - 84, XP005336495

DOI:   http://dx.doi.org/10.1016/j.patbio.2005.03.003
   ANONYMOUS: "XRP6258 Plus Prednisone Compared to Mitoxantrone Plus Prednisone in Hormone Refractory Metastatic Prostate Cancer (TROPIC)", THE CLINICAL STUDY PAGE ON CLINICALTRIALS.GOV FOR STUDY NCT00417079, 11 September 2009 (2009-09-11), XP055722791, Retrieved from the Internet
   ANONYMOUS: "Cabazitaxel (XRP-6258) for hormone refractory, metastatic prostate cancer - second line after docetaxel", April 2009 (2009-04-01), XP055722792, Retrieved from the Internet
   ERIC WINQUIST; MACKENZIE MARY J; RODRIGUES GEORGE: "Open clinical uro-oncology trials in Canada", THE CANADIAN JOURNAL OF UROLOGY, February 2008 (2008-02-01), pages 3942 - 3949, XP055746783
OppositionWO2005028462
 US2005065138
 US2005065138
 US25616009
 US39031010
 US35583410
 US35588810
 US36992910
 US38393310
 US38996910
 WO2005028462
 WO9630355
 US25616009
 US2005065138
 US25616009
 US39031010
 US35583410
 US35588810
 US36992910
 US38393310
 US38996910
   ANONYMOUS: "XRP6258 Plus Prednisone Compared to Mitoxantrone Plus Prednisone in Hormone Refractory Metastatic Prostate Cancer (TROPIC)", CLINICALTRIALS NCT00417079, 11 September 2009 (2009-09-11), XP055722791, Retrieved from the Internet
   NHSC: "Cabazitaxel (XRP-6258) for hormone refractory, metastatic prostate cancer - second line after docetaxel", GUIDANCE DOCUMENT, 1 April 2009 (2009-04-01), pages 1 - 5, XP055722792, Retrieved from the Internet
   DR BARRY MIRTSCHING: "Prostate Cancer clinical trials in Dallas, Texas Area", THE PROSTATE CANCER BLOG, 12 October 2007 (2007-10-12), XP055789938, Retrieved from the Internet
   MITA A. C. ET AL.: "Phase I and Pharmacokinetic Study of XRP6258 (RPR 116258A), a Novel Taxane, Administered as a 1-Hour Infusion Every 3 Weeks in Patients with Advanced Solid Tumors", CLIN CANCER RES, vol. 15, no. 2, 15 January 2009 (2009-01-15), pages 723 - 730, XP002623316

DOI:   http://dx.doi.org/10.1158/1078-0432.ccr-08-0596
   ANONYMOUS: "XRP6258 Plus Prednisone Compared to Mitoxantrone Plus Prednisone in Hormone Refractory Metastatic Prostate Cancer", PROTOCOL OF CLINICAL TRIALS NCT00417079, 14 November 2008 (2008-11-14), XP055790142, Retrieved from the Internet
   E.K. BEARDSLEY: "Systemic therapy after firsMine docetaxel in metastatic castration-resistant prostate cancer", CURR. OP. SUPPORT. PALLIAT. CARE, vol. 2, no. 3, 1 September 2008 (2008-09-01), pages 161 - 166, XP009149037

DOI:   http://dx.doi.org/10.1097/SPC.0b013e32830c48a3
   A.C. MITA: "Phase I and Pharmacokinetic Study of XRP6258 (RPR 116258A), a Novel Taxane, Administered as a 1-Hour Infusion Every 3 Weeks in Patients with Advanced Solid Tumors", CLIN. CANCER RES., vol. 15, no. 2, 15 January 2009 (2009-01-15), pages 723 - 730, XP002623316

DOI:   http://dx.doi.org/10.1158/1078-0432.ccr-08-0596
   E. GALLETTI: "Paclitaxel And Docetaxel Resistance: Molecular Mechanisms and Development of New Generation Taxanes", CHEMMEDCHEM, vol. 2, 27 June 2007 (2007-06-27), pages 920 - 942, XP055710948
   ANONYMOUS: "Cabazitaxel XRP-6258 for hormone refractory prostate cancer", NHSC, 1 April 2009 (2009-04-01), pages 1 - 5, XP055722792, Retrieved from the Internet
   SANOFI: "Sanofi-aventis provides an R&D pipelines updates", SANOFI-AVENTIS PRESS RELEASE, 22 December 2009 (2009-12-22), pages 1 - 2, XP055790137
   L. BO: "Un projet de mdicament stopp in extremis", LES ECHOS, 22 December 2009 (2009-12-22), XP055789957, Retrieved from the Internet
   "XRP6258 Plus Prednisone Compared to Mitoxantrone Plus Prednisone in Hormone Refractory Metastatic Prostate Cancer (TROPIC", THE CLINICAL STUDY PAGE ON CLINICALTRIALS.GOV FOR STUDY NCT00417079, 11 September 2009 (2009-09-11), XP055609984
   GALLETTI ELENA, MAGNANI M ET AL: "Paclitaxel and Docetaxel Resistance: Molecular Mechanisms and Development of New Generation Taxanes", vol. 2, no. 7, 27 June 2007 (2007-06-27), pages 920 - 942, XP055710948, DOI: 10.1002/cmdc.200600308
   ATTARD G., GREYSTOKE G; KAYE A; DE BONO S; J: "Update on tubulin-binding agents", PATHOLOGIE ET BIOLOGIE, vol. 54, no. 2, 1 March 2006 (2006-03-01), pages 72 - 84, XP005336495, DOI: 10.1016/j.patbio.2005.03.003

DOI:   http://dx.doi.org/10.1016/j.patbio.2005.03.003
   A. MITA ET AL.: "Phase I and Pharmacokinetic Study of XRP6258 (RPR 116258A), a Novel Taxane, Administered as a 1-Hour Infusion Every 3 Weeks in Patients with Advanced Solid Tumours", CLINICAL CANCER RESEARCH, vol. 15, no. 2, 15 January 2009 (2009-01-15), pages 723 - 730, XP002623316, DOI: 10.1158/1078-0432.ccr-08-0596

DOI:   http://dx.doi.org/10.1158/1078-0432.ccr-08-0596
   X. PIVOT, KORALEWSKI P; HIDALGO J L; CHAN A; GONALVES A; SCHWARTSMANN G; ASSADOURIAN S; LOTZ J P: "A multicentre phase II study of XRP6258 administered as 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients", ANNALS OF ONCOLOGY, vol. 19, no. 9, 1 September 2008 (2008-09-01), pages 1547 - 1552, XP002551475, DOI: 10.1093/annonc/mdn171

DOI:   http://dx.doi.org/10.1093/annonc/mdn171
   ANONYMOUS: "XRP6258 Plus Prednisone Compared to Mitoxantrone Plus Prednisone in Hormone Refractory Metastatic Prostate Cancer (TROPIC)", WEB ARCHIVE, 11 September 2009 (2009-09-11), pages 1 - 5, XP055722791
   DR BARRY MIRTSCHING: "Prostate Cancer Clinical Trials in Dallas , Texas Area", THE PROSTATE CANCER BLOG, 12 October 2007 (2007-10-12), pages 1 - 4, XP055789938
   DR BARRY MIRTSCHING: "Center for Oncology Research & Treatment-Dallas, TX Innovative Cancer Treatment", BLOG POSTS, 6 July 2007 (2007-07-06), pages 1 - 2, XP055844989
   MITA ET AL.: "Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors", CLIN CANCER RES, vol. 15, no. 2, 2009, pages 723 - 730, XP002623316

DOI:   http://dx.doi.org/10.1158/1078-0432.ccr-08-0596
   BEARDSLEY EMMA K; CHI KIM N: "Systemic therapy after first-line docetaxel in metastatic castration-resistant prostate cancer", CURR OP SUPPOR PALLIAT CARE, vol. 2, no. 3, 2008, pages 161 - 166, XP009149037

DOI:   http://dx.doi.org/10.1097/SPC.0b013e32830c48a3
   ANONYMOUS: "INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE", GENERAL CONSIDERATIONS FOR CLINICAL TRIALS E8, 17 July 1997 (1997-07-17), pages 1 - 17, XP055845138
   ANONYMOUS: "EMEA General Guidance for Clinical Trials; ICH Topic E 8 - General Considerations for Clinical Trials", EMEA GENERAL GUIDANCE FOR CLINICAL TRIALS, March 1998 (1998-03-01), pages 1 - 14, XP002744728
   "JAEHDE, LEHRBUCH DER KLINISCHEN PHARMAZIE", 1998, Stuttgart, ISBN: 9783804716216, article JAEHDE: "KLINISCHE PRFUNG VON ARZNEIMITTELN", pages: 103 - 114, XP055845146
   PIVOT X., P KORALEWSKI, J L HIDALGO, A CHAN, A GONALVES, G SCHWARTSMANN, S ASSADOURIAN, J P LOTZ: "A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients", ANNALS OF ONCOLOGY, vol. 19, 2008, pages 1547 - 1552, XP002551475

DOI:   http://dx.doi.org/10.1093/annonc/mdn171
   ATTARD ET AL., PATHOLOGIE BIOLOGIE, 2006, pages 72 - 84
   TANNOCK IAN F; WIT DE RONALD; BERRY WILLIAM R; ET AL: "Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer", N ENGL J MED, vol. 351, no. 15, 2004, pages 1502 - 1512, XP002623317

DOI:   http://dx.doi.org/10.1056/NEJMoa040720
   ROSENBERG J. E., WEINBERG VK, KELLY WK, MICHAELSON D, HUSSAIN MH, WILDING G, GROSS M, HUTCHEON D, SMALL EJ: "Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients : randomized phase 2 study of ixabepilone or mitoxantrone and prednisone.", CANCER, vol. 110, no. 3, 2007, pages 556 - 563, XP055845173
   CORA N STERNBERG , IWONA A SKONECZNA, DANIEL CASTELLANO, CHRISTINE THEODORE, NORMAND BLAIS, ERIC VOOG, JOAQUIM BELLMUNT, FRANK PET: "Larotaxel with Cisplatin in the first-line treatment of locally advanced/metastatic urothelial tract or bladder cancer: a randomized, active-controlled, phase III trial (CILAB)", ONCOLOGY, vol. 85, no. 4, 2013, pages 208 - 215, XP055845187
   ALLER A W; KRAUS L A; BISSERY M C: "Abstract 1923: IN VITRO ACTIVITY OF TXD258 IN CHEMOTHERAPEUTIC RESISTANT TUMOR CELL LINES", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, vol. 41, 2000, pages 302, XP001525864 * D1a Protocol of clinical trial NCT00417079: "XRP6258 Plus Prednisone Compared to Mitoxantrone Plus Prednisone in Hormone Refractory Metastatic Prostate Cancer (TROPIC)" 14 November 2008 *
   SNCHEZ CATHERINE, PATRICIA MENDOZA, HCTOR R CONTRERAS, JORGE VERGARA, JAMES A MCCUBREY, CHRISTIAN HUIDOBRO, ENRIQUE A CASTELLN: "Expression of Multidrug Resistance Proteins in Prostrate Cancer is Related With Cell Sensitivity to Chemotherapeutic Drugs", PROSTATE, vol. 69, no. 15 September, 2009, pages 1448 - 1459, XP055845205
   ANONYMOUS: "XRP6258 and XRP9881 Novel Taxoids", AVENTIS PHARMACEUTICALS, 2003, pages 1 - 2, XP055845209
   ANONYMOUS: "XRP6258 Plus Prednisone Compared to Mitoxantrone Plus Prednisone in Hormone Refractory Metastatic Prostate Cancer (TROPIC)", THE CLINICAL STUDY PAGE ON CLINICALTRIALS.GOV FOR STUDY NCT00417079, 11 September 2009 (2009-09-11), XP055722791, Retrieved from the Internet [retrieved on 20200817]
   ANONYMOUS: "Cabazitaxel (XRP-6258) for hormone refractory, metastatic prostate cancer - second line after docetaxel", NATIONAL HORIZON SCANNING CENTRE (NHSC), 1 April 2009 (2009-04-01), pages 1 - 5, XP055722792, Retrieved from the Internet [retrieved on 20200817]
   ALAIN C. MITA ET AL: "Phase I and Pharmacokinetic Study of XRP6258 (RPR 116258A), a Novel Taxane, Administered as a 1-Hour Infusion Every 3 Weeks in Patients with Advanced Solid Tumors", CLINICAL CANCER RESEARCH, ASSOCIATION FOR CANCER RESEARCH, US, vol. 15, no. 2, 15 January 2009 (2009-01-15), US, pages 723 - 730, XP002623316, ISSN: 1078-0432, DOI: 10.1158/1078-0432.ccr-08-0596

DOI:   http://dx.doi.org/10.1158/1078-0432.ccr-08-0596
   BEARDSLEY EMMA K; CHI KIM N: "Systemic therapy after first-line docetaxel in metastatic castration-resistant prostate cancer.", CURRENT OPINION IN SUPPORTIVE AND PALLIATIVE CARE, WOLTERS KLUWER HEALTH LIPPINCOTT WILLIAMS & WILKINS, vol. 2, no. 3, 1 September 2008 (2008-09-01), pages 161 - 166, XP009149037, ISSN: 1751-4266, DOI: 10.1097/SPC.0b013e32830c48a3

DOI:   http://dx.doi.org/10.1097/SPC.0b013e32830c48a3
   E GALLETTI, MAGNANI M ET AL: "Paclitaxel And Docetaxel Resistance: Molecular Mechanisms and Development of New Generation Taxanes", CHEMMEDCHEM, vol. 2, 27 June 2007 (2007-06-27), pages 920 - 942, XP055710948
   ANONYMOUS: "Sanofi-aventis provides R&D Pipeline update", SANOFI-AVENTIS PRESS RELEASE, 21 December 2009 (2009-12-21), pages 1 - 2, XP055874730
   PIVOT X, ET AL: "A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients.", ANNALS OF ONCOLOGY : OFFICIAL JOURNAL OF THE EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY / ESMO SEP 2008, vol. 19, no. 9, 1 September 2008 (2008-09-01), pages 1547 - 1552, XP002551475, DOI: 10.1093/annonc/mdn171

DOI:   http://dx.doi.org/10.1093/annonc/mdn171
   DE BONO, J.S. ET AL: "Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial", THE LANCET, ELSEVIER, AMSTERDAM, NL, vol. 376, no. 9747, 2 October 2010 (2010-10-02), AMSTERDAM, NL , pages 1147 - 1154, XP027373072, ISSN: 0140-6736, DOI: 10.1016/S0140-6736(10)61389-X

DOI:   http://dx.doi.org/10.1016/S0140-6736(10)61389-X
   ANONYMOUS: "Guideline on the evaluation of anticancer medicinal products in man", EMA/CHMP/205/95 REV.5, 22 September 2017 (2017-09-22), pages 1 - 43, XP055621264, [retrieved on 20190911]
   SUMANTA KUMAR PAL, PRZEMYSLAW TWARDOWSKI, AND OLIVER SARTOR: "Critical appraisal of cabazitaxel in the management of advanced prostate cancer", CLINICAL INTERVENTIONS IN AGING, vol. 5, 3 December 2010 (2010-12-03), pages 395 - 402, XP009144702, DOI: 10.2147/CIA.S14570

DOI:   http://dx.doi.org/10.2147/CIA.S14570
   ATTARD G ET AL: "Update on tubulin-binding agents", PATHOLOGIE BIOLOGIE, L'EXPANSION SCIENTIFIQUE FRANCAISE, PARIS., FR, vol. 54, no. 2, 1 March 2006 (2006-03-01), FR , pages 72 - 84, XP024926230, ISSN: 0369-8114, DOI: 10.1016/j.patbio.2005.03.003

DOI:   http://dx.doi.org/10.1016/j.patbio.2005.03.003
   TANNOCK IAN F ET AL: "Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.", NEW ENGLAND JOURNAL OF MEDICINE, THE - NEJM, MASSACHUSETTS MEDICAL SOCIETY, US, vol. 351, no. 15, 7 October 2004 (2004-10-07), US , pages 1502 - 1512, XP002623317, ISSN: 1533-4406, DOI: 10.1056/NEJMoa040720

DOI:   http://dx.doi.org/10.1056/NEJMoa040720
   ANONYMOUS: "JEVTANA® 60 mg Konzentrat und Lösungsmittel zur Herstellung einer Infusionlösung", SANOFI GENZYME FACHINFORMATION, 1 April 2017 (2017-04-01), XP055617507 * D1a Protocol of clinical trial NCT00417079: "XRP6258 Plus Prednisone Compared to Mitoxantrone Plus Prednisone in Hormone Refractory Metastatic Prostate Cancer (TROPIC)" 14 November 2008 *
   ERIC WINQUIST, MACKENZIE MARY J, RODRIGUES GEORGE: "Open clinical uro-oncology trials in Canada", THE CANADIAN JOURNAL OF UROLOGY, vol. 15, no. 1, 1 February 2008 (2008-02-01), pages 3942 - 3949, XP055746783
   ANONYMOUS: "Cabazitaxel (XRP-6258) for hormone refractory, metastatic prostate cancer - second line after docetaxel", NATIONAL HORIZON SCANNING CENTRE (NHSC), 1 April 2009 (2009-04-01), pages 1 - 5, XP055722792, Retrieved from the Internet [retrieved on 20200817]
   DR BARRY MIRTSCHING: "Prostate Cancer clinical trials in Dallas, Texas Area", THE PROSTATE CANCER BLOG, 12 October 2007 (2007-10-12), XP055789938, Retrieved from the Internet [retrieved on 20210325]
   ANONYMOUS: "XRP6258 Plus Prednisone Compared to Mitoxantrone Plus Prednisone in Hormone Refractory Metastatic Prostate Cancer (TROPIC)", CLINICALTRIALS.GOV NCT00417079, 14 November 2008 (2008-11-14), pages 1 - 5, XP055876295, Retrieved from the Internet [retrieved on 20220105]
   TANNOCK IAN F , WIT DE RONALD, BERRY WILLIAM R, ET AL: "Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.", NEW ENGLAND JOURNAL OF MEDICINE, THE - NEJM, MASSACHUSETTS MEDICAL SOCIETY, US, vol. 351, no. 15, 7 October 2004 (2004-10-07), US , pages 1502 - 1512, XP002623317, ISSN: 1533-4406, DOI: 10.1056/NEJMoa040720

DOI:   http://dx.doi.org/10.1056/NEJMoa040720
   MITA ET AL.: "Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors", CLIN CANCER RES, vol. 15, no. 2, 15 January 2009 (2009-01-15), pages 723 - 30, XP002623316, DOI: 10.1158/1078-0432.ccr-08-0596

DOI:   http://dx.doi.org/10.1158/1078-0432.ccr-08-0596
   E GALLETTI, MAGNANI M ET AL: "Paclitaxel And Docetaxel Resistance: Molecular Mechanisms and Development of New Generation Taxanes", CHEMMEDCHEM, vol. 2, 27 June 2007 (2007-06-27), pages 920 - 942, XP055710948
   BEARDSLEY EMMA K; CHI KIM N: "Systemic therapy after first-line docetaxel in metastatic castration-resistant prostate cancer.", CURRENT OPINION IN SUPPORTIVE AND PALLIATIVE CARE, WOLTERS KLUWER HEALTH LIPPINCOTT WILLIAMS & WILKINS, vol. 2, no. 3, 1 September 2008 (2008-09-01), pages 161 - 166, XP009149037, ISSN: 1751-4266, DOI: 10.1097/SPC.0b013e32830c48a3 * D1a Protocol of clinical trial NCT00417079: "XRP6258 Plus Prednisone Compared to Mitoxantrone Plus Prednisone in Hormone Refractory Metastatic Prostate Cancer (TROPIC)" 14 November 2008 *

DOI:   http://dx.doi.org/10.1097/SPC.0b013e32830c48a3
   SUMANTA KUMAR PAL, PRZEMYSLAW TWARDOWSKI, AND OLIVER SARTOR: "Critical appraisal of cabazitaxel in the management of advanced prostate cancer", CLINICAL INTERVENTIONS IN AGING, vol. 5, 3 December 2010 (2010-12-03), pages 395 - 402, XP009144702, DOI: 10.2147/CIA.S14570

DOI:   http://dx.doi.org/10.2147/CIA.S14570
   ANONYMOUS: "Sanofi-aventis provides an R&D Pipeline update", SANOFI AVENTIS, 21 December 2009 (2009-12-21), pages 1 - 2, XP055894891
   SARTOR ALTON OLIVER: "Novel Antitumoral use of Cabazitaxel", DECLARATION OF DR SARTOR, 23 December 2020 (2020-12-23), pages 1 - 11, XP055894896
   "Extract related to trial n. NCT00417079", NCT00417079, 11 September 2009 (2009-09-11), XP055722791
   ANONYMOUS: "Cabazitaxel (XRP-6258) for hormone refractory, metastatic prostate cancer - second line after docetaxel", NATIONAL HORIZON SCANNING CENTRE (NHSC), 1 April 2009 (2009-04-01), pages 1 - 5, XP055722792, Retrieved from the Internet [retrieved on 20200817]
   THE PROSTATE CANCER BLOG, 12 October 2007 (2007-10-12), XP055789938
   ANONYMOUS: "XRP6258 Plus Prednisone Compared to Mitoxantrone Plus Prednisone in Hormone Refractory Metastatic Prostate Cancer (TROPIC)", CLINICALTRIALS.GOV NCT00417079, 14 November 2008 (2008-11-14), pages 1 - 5, XP055876295, [retrieved on 20220105]
   ANONYMOUS: "Sanofi-aventis provides R&D Pipeline update", SANOFI-AVENTIS PRESS RELEASE, 21 December 2009 (2009-12-21), pages 1 - 2, XP055874730
   SARTOR OLIVER, WEINBERGER MARIBETH, MOORE ANDREA, LI AILING, FIGG WILLIAM D: "Effect of prednisone on prostate-specific antigen in patients with hormone-refractory prostate cancer", UROLOGY., BELLE MEAD, NJ, US, vol. 52, no. 2, 1 August 1998 (1998-08-01), US , pages 252 - 256, XP055797370, ISSN: 0090-4295, DOI: 10.1016/S0090-4295(98)00149-6

DOI:   http://dx.doi.org/10.1016/S0090-4295(98)00149-6
   ANONYMOUS: "XRP6258 Plus Prednisone Compared to Mitoxantrone Plus Prednisone in Hormone Refractory Metastatic Prostate Cancer (TROPIC)", THE CLINICAL STUDY PAGE ON CLINICALTRIALS.GOV FOR STUDY NCT00417079, 11 September 2009 (2009-09-11), XP055722791, Retrieved from the Internet [retrieved on 20200817]
   ANONYMOUS: "Cabazitaxel (XRP-6258) for hormone refractory, metastatic prostate cancer - second line after docetaxel", NATIONAL HORIZON SCANNING CENTRE (NHSC), 1 April 2009 (2009-04-01), pages 1 - 5, XP055722792, Retrieved from the Internet [retrieved on 20200817]
   ERIC WINQUIST, MACKENZIE MARY J, RODRIGUES GEORGE: "Open clinical uro-oncology trials in Canada", THE CANADIAN JOURNAL OF UROLOGY, vol. 15, no. 1, 1 February 2008 (2008-02-01), pages 3942 - 3949, XP055746783
   BEARDSLEY EMMA K; CHI KIM N: "Systemic therapy after first-line docetaxel in metastatic castration-resistant prostate cancer.", CURRENT OPINION IN SUPPORTIVE AND PALLIATIVE CARE, WOLTERS KLUWER HEALTH LIPPINCOTT WILLIAMS & WILKINS, vol. 2, no. 3, 1 September 2008 (2008-09-01), pages 161 - 166, XP009149037, ISSN: 1751-4266, DOI: 10.1097/SPC.0b013e32830c48a3

DOI:   http://dx.doi.org/10.1097/SPC.0b013e32830c48a3
   ALAIN C. MITA, LOUIS J. DENIS, ERIC K. ROWINSKY, JOHANN S. DEBONO, ANDREW D. GOETZ, LEONEL OCHOA, BAHRAM FOROUZESH, MURALIDHAR BEE: "Phase I and Pharmacokinetic Study of XRP6258 (RPR 116258A), a Novel Taxane, Administered as a 1-Hour Infusion Every 3 Weeks in Patients with Advanced Solid Tumors", CLINICAL CANCER RESEARCH, ASSOCIATION FOR CANCER RESEARCH, US, vol. 15, no. 2, 15 January 2009 (2009-01-15), US, pages 723 - 730, XP002623316, ISSN: 1078-0432, DOI: 10.1158/1078-0432.ccr-08-0596

DOI:   http://dx.doi.org/10.1158/1078-0432.ccr-08-0596
   ANONYMOUS: "Junta General de Accionistas 2003", ZELTIA, 1 January 2003 (2003-01-01), pages 1 - 61, XP055911158, [retrieved on 20220411]
   INFORMATION FOR THE PATIENT CONCERNING THE CLINICAL STUDY 42446 02 041
   STAFF REUTERS, VIEHBACHER D , DISCOVER THOMSON, REUTERS: "Update 1-Sanofi CEO to give mid-term view at end of 2009", REUTERS, 21 December 2009 (2009-12-21), pages 1 - 4, XP055912064
   "XRP6258 Plus Prednisone Compared to Mito-xantrone Plus Prednisone in Hormone Refractory Metastatic Prostate Cancer (TROPIC", CLINICALTRIALS.GOV, 11 September 2009 (2009-09-11)
   ANONYMOUS: "Taxotere SUMMARY OF PRODUCT CHARACTERISTICS", TAXOTERE, November 2008 (2008-11-01), pages 1 - 109, XP055912098
   ANONYMOUS: "Cabazitaxel (XRP-6258) for hormone refractory, metastatic prostate cancer - second line after docetaxel", NHSC GUIDANCE DOCUMENT, April 2009 (2009-04-01), pages 1 - 5, XP055722792, Retrieved from the Internet
   ANONYMOUS: "XRP6258 Plus Prednisone Compared to Mitoxantrone Plus Prednisone in Hormone Refractory Metastatic Prostatae Cnacer (TROPIC)", CLINICALTRIAL.GOV NCT00417079, 11 September 2009 (2009-09-11), pages 1 - 4, XP055911510
   A.C. MITA ET AL.: "Phase I and Pharmacokinetic Study of XRP6258 (RPR116258A), a Novel Taxane, Administered as a 1-Hour Infusion Every 3 Weeks in Patients with Advanced Solid Tumors", CLIN . CANCER RES., vol. 15, 2009, pages 723 - 730, XP002623316, DOI: 10.1158/1078-0432.ccr-08-0596

DOI:   http://dx.doi.org/10.1158/1078-0432.ccr-08-0596
   BARRY MIRTSCHING: "Prostate Cancer clinical trials in Dallas, Texas Area", THE PROSTATE CANCER BLOG, 10 November 2007 (2007-11-10), pages 1 - 3, XP055789938
   SANOFI: "Sanofi-aventis provides an R&D pipelines updates", SANOFI-AVENTIS PRESS RELEASE, 22 December 2009 (2009-12-22), pages 1 - 2, XP055790137 * D1a Protocol of clinical trial NCT00417079: "XRP6258 Plus Prednisone Compared to Mitoxantrone Plus Prednisone in Hormone Refractory Metastatic Prostate Cancer (TROPIC)" 14 November 2008 *
   ANONYMOUS: "HIGHLIGHTS OF PRESCRIBING INFORMATION - JEVTANA (cabazitaxel)", JEVTANA, June 2010 (2010-06-01), pages 1 - 25, XP055770144
   J.-S. DE BONO ET AL.: "Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomized open-label trial", LANCET, vol. 376, no. 9747, 2010, pages 1147 - 1154, XP027598276

DOI:   http://dx.doi.org/10.1016/S0140-6736(10)61389-X
   SARTOR, O.: "Endpoints in prostate cancer clinical trials", UROLOGY, vol. 60, 2002, pages 101 - 108, XP055912110

DOI:   http://dx.doi.org/10.1016/S0090-4295(02)01585-6
   DE BONO, J.S. ; OUDARD, S. ; OZGUROGLU, M. ; HANSEN, S. ; MACHIELS, J.P. ; KOCAK, I. ; GRAVIS, G. ; BODROGI, I. ; MACKENZIE, M.J. : "Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial", THE LANCET, ELSEVIER, AMSTERDAM, NL, vol. 376, no. 9747, 2 October 2010 (2010-10-02), AMSTERDAM, NL , pages 1147 - 1154, XP027373072, ISSN: 0140-6736, DOI: 10.1016/S0140-6736(10)61389-X

DOI:   http://dx.doi.org/10.1016/S0140-6736(10)61389-X
   GOETZ A. D., DENIS L.J., ROWINSKY L., OCHOA K., MOLPUS B., DEBLONDE D. ET AL.: "419. Phase I and Pharmacokinetic Study of RPR116258A, a Novel Taxane Derivative, Administered Intravenously over 1 Hour Every 3 Weeks", CLINICAL PHARMOCOLOGY - PROCEEDINGS OF ASCO, vol. 20, 1 January 2001 (2001-01-01), pages 106a, XP093121715
   BISSERY MARIE-CHRISTINE, H, BOUCHARD, J. F RIOU, P. VRIGNAUD. C. COMBEAU, J. D BOURZAT, A. COMMERCON. AND F. LAVELLE : "#1364 PRECLINICAL EVALUATION OF TX0258. A NEW TAXOID", PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS - PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, vol. 41, 1 March 2000 (2000-03-01), pages 214, XP093121720
   S. OUDARD, P. BEUZEBOC, E. VOOG, P. BARTHELEMY, A. THIERY-VUILLEMIN, M. BENNAMOUN, A. HASBINI, K. ALDABBAGH, C. SALDANA, E. SEVIN,: "Cabazitaxel every 2 weeks versus every 3 weeks in older patients with metastatic castration-resistant prostate cancer (mCRPC): The CABASTY randomized phase III trial", ANNALS OF ONCOLOGY , vol. 33, no. S7, 1 January 2022 (2022-01-01), pages S1164 - S1165, XP093128775, DOI: 10.1016/j.annonc.2022.07.1495

DOI:   http://dx.doi.org/10.1016/j.annonc.2022.07.1495
   RAMESH K. RAMANATHAN ; JOEL PICUS ; HARALAMBOS RAFTOPOULOS ; STEPHEN BERNARD ; A. CRAIG LOCKHART ; GARY FRENETTE ; JOHN MACDONALD : "A phase II study of milataxel: a novel taxane analogue in previously treated patients with advanced colorectal cancer", CANCER CHEMOTHERAPY AND PHARMACOLOGY, vol. 61, no. 3, 22 May 2007 (2007-05-22), Berlin, DE , pages 453 - 458, XP019561460, ISSN: 1432-0843, DOI: 10.1007/s00280-007-0489-5
   ZIADA ALI, BARQAWI ALBAHA, GLODE L. MICHAEL, VARELLA-GARCIA MARILEILA, CRIGHTON FRANCES, MAJESKI SUSAN, ROSENBLUM MARK, KANE MADEL: "The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial", THE PROSTATE, vol. 60, no. 4, 1 September 2004 (2004-09-01), US , pages 332 - 337, XP093087027, ISSN: 0270-4137, DOI: 10.1002/pros.20065

DOI:   http://dx.doi.org/10.1002/pros.20065
   ERIC J. SMALL; JOSEPH FONTANA; NIZAR TANNIR; ROBERT S. DIPAOLA; GEORGE WILDING; MARK RUBIN; RENEE BAILEY IACONA; FAIROOZ F. KABBIN: "A phase II trial of gefitinib in patients with nonmetastatic hormonerefractory prostate cancer", BJU INTERNATIONAL, vol. 100, no. 4, 3 September 2007 (2007-09-03), Hoboken, USA, pages 765 - 769, XP072220668, ISSN: 1464-4096, DOI: 10.1111/j.1464-410X.2007.07121.x

DOI:   http://dx.doi.org/10.1111/j.1464-410X.2007.07121.x
   ANONYMOUS: "Novacea, Inc. Announces Preliminary Findings From Data Analysis of Ascent-2 Phase 3 Trial", 4 June 2008 (2008-06-04), pages 1 - 1, XP093128779, Retrieved from the Internet [retrieved on 20240207]
   MULCAHY NICK: "Phase 3 Trial of Immunotherapy for Metastatic Prostate Cancer Terminated", 17 October 2008 (2008-10-17), pages 1 - 2, XP093128784, Retrieved from the Internet [retrieved on 20240207]
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.